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                                                                           INTRODUCTION 
SIDDHA SYSTEM 
Siddha System of Medicine is an integrated part of Indian System of medicine, 
which is very potent and unique system when compared with other traditional systems in 
existence. Siddha Medicine is contributing much to the health care of human beings  
Siddha medicine employs a variety of herbs and minerals, many of which were 
developed in the ancient past under advanced scientific techniques. The development of 
medicine has been a continuous process in Asia although it has always taken a more 
natural approach to healing than western medicine.  
Siddha system clearly lays down the general principles of body constituents in the 
classic Bootha system. Siddhars hold that the universe is a macrocosm made up of the 
five primordial elements or Boothas, viz Nilam (Earth), Neer (Water), Thee (Fire), Vali 
(wind) and Veli (Space) and the human being is a microcosm made up of the same five 
elements.                                                    
   “mz;lj;jpYs;sNj gpz;lk; 
                 gpz;lj;jpYs;sNj mz;lk; 
                 mz;lKk; gpz;lKk; xd;Nw 
                 mwpe;Jjhd; ghHf;Fk; NghNj.” 
                                  - rl;lKdp Qhdk; 
Siddha System propounded by the Siddhars defines health as a Perfect state of 
Physical, Psychological, Social and Spiritual well being of an individual. The system not 
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only deals with medicine, but with spirituality, righteous way of living, rejuvenation and 
means of attainment of perfection.  
No doubt, the Siddha System of Medicine is one among the foremost of all other 
medical systems of the world. The other systems are concerned only with treatment and 
preventive aspects. But Siddha system is the only system which bestows immortality.  
 The Siddhars were the greatest spiritual scientists and; they were the seekers of 
truth. “SIDDHU” means “knowledge or wisdom” and “SIDDHI” means “attainment of 
perfection”. One who attains perfection in life is called as Siddhar. They had thoroughly 
studied human body, all kinds of plants, minerals, metals and other poisonous drugs and 
their physical and chemical properties. They are follower of Siva cult. They are experts in 
Alchemy, Yoga and Kayakalpa, the science of Elixir and also in the field of literature, 
philosophy, astrology etc. They held that the body is the only instrument with which one 
could attain success in spiritual evolution and thereby get rid of diseases, decay and 
death.  
Many chronic diseases, considered incurable in western medicine, can be treated 
successfully with Siddha medicine. Most medicines are for the most part natural and 
processed in such a way as to be readily absorbed within each cell in the body, giving it 
proper nourishment to sustain a long and healthy life. As the western medical techniques 
are, for the most part, very expensive for the average Indian citizens, they generally seek 
the services of a Siddha physician or other holistic practitioners. 
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Garpavaayu (Poly Cystic Ovarian Disease)  
This PCOD is correlated to GARPAVAYU mentioned in Agathya 
mamunivar ayulvedham 1200 . As per Saint Agathyar, Garpavayu with the symptoms of 
irregular menstruation, dysmenorrhea, infertility, missed abortions, obesity, low back 
pain and constipation. closely resembles PCOD in Modern medicine. 
Other names for Polycystic ovarian disease (PCOD) are polycystic ovarian 
syndrome (PCOS) or the Stein-Leventhal syndrome. Polycystic ovarian disease (PCOD) 
is currently considered the most frequent cause of female infertility. It is also closely 
associated with syndrome XX, which, in turn, is closely linked with premature and 
excessive mortality 
Polycystic ovarian disease (PCOD) is the most important endocrine abnormality 
that affects women in reproductive age. Polycystic ovarian disease (PCOD) is 
characterized by hyperandrogenemia, ovulatory dysfunction and polycystic ovaries 
(PCO). The increased androgen production in PCOD comes primarily from the ovaries. 
However, in about 40% of patients there is excessive adrenal androgen production 
Patients suffering from polycystic ovarian disease ( PCOD ) have multiple small 
cysts in their ovaries. These cysts occur when the regular changes of a normal menstrual 
cycle are disrupted. The ovary is enlarged; and produces excessive amounts of androgen 
and estrogenic hormones. This excess, along with the absence of ovulation, may cause 
infertility.  
A "wedge resection" of the ovaries may be used to remove cysts but it still allows 
contraception (since ova don't mature) and, weight reduction. Maintaining general good 
health and eliminating the complications of obesity is essential. 
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NEED FOR THIS STUDY 
The change of lifestyle has created a lot of melodies. Nowadays PCOD is one of 
the causes for female infertility and it may be due to stress and altered dietary habits. 
During 2005 – 2006, approximately 1000 cases of Soothaga noi (including 
GARPAVAYU) were recorded in out patient department of Ayothidoss Pandithar 
Hospital of the National Institute of Siddha The PCOD Symptoms are comparable to the 
Garpavaayu disease in Siddha System.  
Though the modern medicine has advanced in its development it still lacks proper 
medicine in some diseases like PCOD, Psoriasis, Etc. Treatment for PCOD in modern 
medicine includes oral contraceptives, Testolactone, and Clomiphene Citrate (chlomid) 
Metformin,etc. These modern medicines were costly for the lower middle class and poor 
people and they have many side effects. E.g. Testolactone, and Clomiphene Citrate 
(chlomid) Metformin,etc.  So there is need for other drugs/therapy which could be safe 
and more effective. Hence I undertook this work. 
 
 
 
 
 
 
 
 
 
 
 
      
 5
AIM AND OBJECTIVES 
The aim of this dissertation work is to study the efficacy of siddha drug Sengottai 
valladhi Legium with Kalinga thylam on Garpavaayu (PCOD). 
  The main objective of this study is to create awareness about Siddha medicine and 
highlight the efficacy of Siddha medicines for the disease Garpavaayu. The following 
specific objectives have been drawn. 
¾ To make a correlative study of this disease Garpavaayu on siddha 
medicine and modern aspects. 
¾ To have an idea about incidence of Garpavaayu with reference to 
age, sex, residence (Nilam), occurrence and duration of the 
disease.  
¾ To make a detailed study of investigations, diagnosis and 
prognosis of the disease. 
¾ To study the course of the disease by Siddha fundamental and 
modern investigations before and after treatment in all patients. 
¾ To do ultrasonography, hematological study, and urine analysis for 
all patients. 
¾ To do the biochemical and Pharmacological analysis of the trial 
drug 
¾ To do the acute and Sub Acute toxicity study of the trial drug. 
¾ To do the Hematological study and in vivo anti – oxidant study of 
trial drug. 
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                                                   REVIEW OF LITERATURE - SIDDHA 
fh;g;g thA  
nghUkp uj;je;jd;id kwpj;Jg; NghjkpfTk; typAz;lhq; 
FUjpNruh tapW typNghq; nfhs;Sq; fh;g;ge;jid aopf;Fk; 
tUbapLg;Gf; File;Jisf;Fk; tyj;ijkpfT kpWf;fpWf;fp 
ngUfg;gizf;F nkdg; nghpNahHNgRq; fHg;g thA tpNj 
- mfj;jpakhKdptH MAs;Ntjk; 1200 
Amenorrhea, Oligomenorrhea followed by Menorrhagea, Dysmenorrhea, 
Infertility, missed abortions, low back pain, Constipation and Obesity are the symptoms 
of Garpavaayu. 
#jff; fpuhzp 
#jfkhk; Nghnjy;yhk; typj;jpuj;jk; 
tPo;tjw;Fk; nrhYehf;Fl; 
Ngjfkha;f; nfLjg;gp typf;fpDk; 
#jff; fpuhzp vd;W Nguhk; 
          - ruNge;jp itj;jpaKiwfs;  fu;g;gpzp ghyNuhf rpfpr;ir 
Painful menstruation and irregular menstruation are the symptoms of Soothaga 
kiraani. 
fHg;g tpg;GUjp Fzk; 
$wplNt tpg;GUjp jhDk; fUJNghy;  
tapw;woNy #jq;fl;Lk;KhwNtjiytypf;Fk; 
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tPl;Lg;gf;fk;tapw;W typapUJilA Kisf;FNkjhd; 
rPwNt GOj;jpuz;L ky kpWf;Fk; 
rpRnfu;g;gk; jupahJ cly; cisf;Fk; 
MwNt apf;Fzq;fs; jhdwpe;J 
mg;gNd kUe;Jz;zr; rpj;jpahNk 
 - ruNge;jp itj;jpaKiwfs;  fu;g;gpzp ghyNuhf rpfpr;ir 
Garpa vippuruthy has the symptoms of head ache, dysmenorrhea, pain  
in the thigh, constipation, infertility and body pain due to the increased Azhal in abdomen 
which inhibits the menstrual flow and leads to the above symptoms 
#jf thA (#rpf thA) 
NrSNk #jfj;jpyf;fpdp tha;T 
nfLj;JtpL khjtplha; fl;bg;NghFk; 
MSNk fUf;FopAk; Jhe;J Njfk;  
mg;gNd AjpukJ mb%yj;jpy; 
ePSNk #jfj;jpy; tha;T Njhd;wp 
Neuhd mbtapW typg;Gf; fhZk; 
ghSNk jiytypf;Fk; tapWisf;Fk; 
gf;Ftkha; kUe;Jz;zj; jPUe;jhNd 
             - Mj;kul;rhkpHjk; vd;Dk; itj;jpa rhurq;fpufk; 
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During menstruation Azhal and vaayu spoils the menstrual flow and cause 
Oligomenorrhea which leads to closure of Karuk kuzhi. Then the Vaayu gets 
accumulated in uterus and causes the lower abdominal pain and head ache. 
 
 
,uj;j #iy 
ghh;j;jplNt kq;ifah;f;F uj;j #iy 
gfWfpNw dbtapw;iwg; gw;wp epw;Fk; 
Nfhh;j;jplNt AjpukJ jpuz;LNkjhd; 
Nfhjpg;ngLj;J khjtplha; fhye;jd;dpw; 
Nrh;j;jplNt #jfq;fy; kpFe;J fhZQ; 
rpWtopaha;f; fUtopAk; gpuz;Lisf;Fk; 
Vh;j;jplNt JilapLg;G Tisr;ryhFk; 
,uj;jkhQ; #iyFz kpJjhd;ghNu 
                  - Mj;kul;rhkph;jk; vd;Dk; itj;jpa rhurq;fpufk; 
Rattha soolai persists in the lower abdomen and causes the collection of menstrual 
excretions along with the heat. This leads to increased menstrual flow, decreased lumen 
of the vagina and causes low back pain. 
fHg;g #iy 
  Nfsha; ngz;Nz #iy fHg;gk; 
   nfLjp nra;Ak; topkhHf;fk; 
  kpshf; fdYk; fUf;Fopapy; 
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   kpFe;k tha;T mDrhpf;Fk; 
  epshr; #jk; jhd; gpuz;L 
   epiwe;j Nrhhp rpRNghthk; 
  jhsh tapWjhd; typf;Fk; 
   jdpj;Jr; Nrug;gyd; nfLNk. 
    - fHg;gf; Nfhs; (rpjk;gujhDg;gps;is) 
Due to Garpasoolai kanal and vaayu increases in karukkuzhi leading to abdominal 
pain, irregular menstruation, collection of menstrual excretion and these all mimic 
symptoms of a pregnant women. 
fHg;g Nuhfk; 
nghUkp jpuz;L fPo;tapw;wpy;  
Gz;Nghyhf kpfNehe;J  
KUtf;Fj;jpf; File;njq;F 
nkhf;fr; RuKk; jiytypAk;  
ntUtf;Fj;jpr; nray; fl;b 
ntbj;Jg; Gz;gl;NlhL gl;Lj; 
jpUit nghUj NkdpaNu 
nra;Akq; nfu;g;g NuhfkpNj 
             - ruNge;jp itj;jpaKiwfs;  fu;g;gpzp ghyNuhf rpfpr;ir 
 Pain in lower abdomen, mild fever, headache, tiredness due to pain are the 
symptoms of Garpa rogam 
 10
#jfj;jpy; thA jq;fpa Fzk; 
khHifgpbj;j NghJte;jpLk; ehb %d;Wk; 
Nrjkhapw;W epd;wNruNt gjpe;Jepw;fpy; 
XJNk #jfj;jpy; Xq;fpa tha;Nt epd;W 
Ngijaha; thijgd;dp gpzpfis tpisf;Fe;jhNd 
    - gjpnzz; rpj;jHfs; ehb rh];j;jpuk; 
If the three naadies are diminished and found mingled with one another then it 
indicates the Vaayu gets accumulated in the uterus. 
ehb 
khjH ifgpbj;j NghJ te;jpLk; thjehb 
jPJwntbj;J gha;e;J rpjwpNa rpyk;gpepd;whw; 
Ngijjd;tapw;wpd; cs;Ns ngLF RNuhzpjNk jq;fp  
thijfs; gz;z khjtpilfhyk; tUj;jk; nra;Ak;  
,Lg;nghL fLj;J nehe;J ,iltplhf; Fj;jYz;lha;  
jLj;jplh fHg;ge;jd;id jq;fplh tz;zk; nra;Ak; 
- gjpnzz; rpj;jHfs; ehb rh];j;jpuk; 
If the vatha naadi gets highly increased and scattered, then it produces pain during 
menstruation, due to collection of menstrual excretion and causes pain in low back and 
lower abdominal areas. At last, these all lead to infertility   
fHg;g Neha; tUk; fhuzk; 
  Royhky; ];jphpfSf;F fh;g;g Neha;jhd; 
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   #o;e;J te;j fhuzj;ijr; nrhy;y NfsPhH 
  moyhNy tpe;Jtij aopj;j ghtk; 
   mQ;rhky; ghyfid nfhd;w ghtk; 
  Fotpapsk; gpQ;R G+g;gwpj;j ghtk; 
   Nfhtpd; fd;Wf;fpd;wp ghy;FBj;j ghtk; 
  Tpisthd tpsk;gapiu aopj;j ghtk; 
   Nkjpdpapy;kylud tpe;ij jhNd 
- khjH kUj;Jtk; (rpjk;gujhDg;gps;is) 
Increased Azhal, killing of new born babies, plucking of flowers in childhood, without 
keeping milk for calf extracting the whole milk from the cow and destroying the crops - 
all these activities cause the female infertility and other gynecological problems 
 
§¿¡ö ¸½¢ôÒ Ó¨È (DIAGNOSIS AND PROGNOSIS) 
In piniyarium muraikal the following principles are followed in Siddha system.  
 
There are  
  1. ¦À¡È¢Â¡ü§È÷¾ø, 
  2. ÒÄÉ¡ÄÈ¢¾ø, 
  3.  Å¢É¡¾ø. 
The maruthuvar (physician) should observe the patient, palpate and interrogate 
the patient thoroughly. This is understood by this maxim.  
                    “Eyes first and most, Hands next and little, mouth last and never” 
 
I, II, PORIYAL ARITHAL AND PULANAL ARITHAL 
Poriyal arithal or understanding by the five organs of perception. 
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Pulanal arithal or understanding by the senses. They are 
1. Mei  –     Ooru (Somatic sense) 
2. Vaai  –   Suvai (Taste) 
3. kan   –     Oli (Vision) 
4. Mookku  – Natram (Smell) 
5. Sevi  – Osai (Sound) 
 
1. Å¢É¡¾ø (INTERROGATION) 
An effective history taking helps one to diagnose properly. By vinathal the 
physician should ask the patient’s native place, mode of living, food habits, personal 
habits, complaints and duration of illness etc. If the patient is deaf or dumb or if the 
patient is a child, the particulars should be obtained from his relatives or parents. 
Poriyal arithal, pulanal arithal and vinathal are applied through eight special tools of 
investigation that is envagai thervugal. 
 
ENVAGAI THERVUGAL 
                  “¿¡ÊôÀÃ¢ºõ ¿¡¿¢Èõ ¦Á¡Æ¢Å¢Æ¢ 
                   ÁÄõ ãò¾¢ÃÁ¢¨Å ÁÕòÐÅÃ¡Ô¾õ” 
                                                    -«¸ò¾¢Â÷ ¿¡Ê 
 
NAADI 
The word pulse means the beating of artery felt with the tip of the fingers. Its rate 
and character indicate a person’s condition of health. It is also understood as the beating, 
throbbing or rhythmical dilatation of arteries as the blood is propelled through them by 
the contraction of the heart in the living body. The term pulse in medical practice is 
usually applied to beat or throb felt in radial artery at the wrist; though it may be felt over 
the temporal, carotid, ulnar, brachial, femoral and other arteries. 
Normally the pulse is recorded in the radial artery in the right hand for the male and left 
hand for the female by keeping the index finger, the middle finger and the ring finger on 
it after gently scrubbing the area. It is one unit in vali as felt by index finger and a half 
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unit in azhal as felt by the middle finger and one fourth of a unit in iyyam as felt by the 
ring finger. The different diseases could easily be diagnosed with aid of the pulse.  
 
             “¿¡Ê ±ýÈ¡ø ¿¡ÊÂøÄ ¿ÃõÀ¢ø ¾¡§É 
                 ¿ÄÁ¡¸ò ÐÊì¸¢ýÈ ÐÊ¾¡Û ÁøÄ 
             ¿¡Ê ±ýÈ¡ø Ä¡¾À¢ò¾ º¢§ÄüÀÉÓÁøÄ 
                 ¿¡Ê ±ØÀò ¾£Ã¡Â¢Ãó ¾¡ÛÁøÄ 
             ¿¡Ê¦ÂýÈ¡ø «ñ¼¦Ãñ¼¦ÁøÄ¡õ 
                 ¿¡Ê ±ØÅ¨¸ò §¾¡üÈòÐûÇ¡ö ¿¢ýÈ 
             ¿¡ÊÂÐ Â¡Ã¡öóÐ À¡÷ò¾¡Ã¡É¡ø 
                 ¿¡ÊÔÚõ ¦À¡Õû¦¾Ã¢óÐ ¿¡ÎÅ¡§Ã”     
                                                              - «¸ò¾¢Â÷ ¿¡Ê 
 
Garpa vaayu naadi 
Aggravation of vali nadi produces symptoms of Garpavaayu. This is emphasized 
in Agathiar nadi, Sathaga nadi and Rathina churukkanadi.     
   
 “Å¡¾¦ÁÛõ ¿¡ÊÂÐ §¾¡ýÈ¢ø 
             º£¾Áó¾¦Á¡Î ÅÂ¢Ú ¦À¡ÕÁø ¾¢Ãðº¢Å¡Ô 
      º£¾ÓÕí ¸¢Ã¡½¢ Á§¸¡¾Ãõ ¿£Ã¡¨Á 
             ¾¢ÃûÅ¡Ô Ý¨Ä ÅÄ¢¸ÎôÒò¾£¨Ã 
      ¿£¾ÓÕí ¸¢ÕÁ¢ÌýÁõ «ñ¼ Å¡¾õ  
             ¿¢¨ÄÔõ¿£÷ì ¸¢Ã¢îºÃí¸û ¾óÐ §Á¸õ” 
                                                            -º¾¸ ¿¡Ê 
 
    “§ÁÅ¢Â Å¡¾ï¦ºöÔõ Ì½ò¨¾ Å¢ÕõÀ¢ì§¸Ù 
           ¾¡Å¢Â ÅÂ¢Õ Áó¾ó ºóÐì¸¡ø ¦À¡ÕòÐ§¿¡Å¡õ 
     §ºÅ¢Â ¾¡Ð¿¡ºî º¢ÚòÐ¼ý º¢Ú¿£÷ Å£Øõ 
           ¸¡Å¢Âí ¸ñ½£É¡§Ç ÁÄÁÐ ¸Õì¸¢¸¡Ûõ” 
                                         - Ãò¾¢É ÍÕì¸¿¡Ê  
 
Derangement of vali azhal naadi produces symptoms of Garpavaayu.        
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             “¦À¡ÕÇ¡É Å¡¾ò¾¢ø À¢ò¾ï §º÷óÐ 
                   ¦À¡ÕóÐ Ì½í¸Ç¡ Ó‰½Å¡Ô ºò¾¢ 
              ¦ºÃ¢Â¡¨Á ÒÇ¢ò§¾ôÀõ ¦À¡ÕÁø ¿£Ã¢ü 
                  º¢ÅôÒÁÄõ À¢Êò¾ÖÕ¾¡Ð ¿ð¼õ” 
 
 
ehb 
khjH ifgpbj;j nghJ te;jpLk; thjehb 
jPJwntbj;J gha;e;J rpjwpNa rpyk;gpepd;whw; 
Ngijjd;tapw;wpd; cs;Ns ngLF RNuhzpjNk jq;fp  
thijfs; gz;z khjtpilfhyk; tUj;jk; nra;Ak;  
,Lg;nghL fLj;J nehe;J ,iltplhf; Fj;jYz;lha;  
jLj;jplh fHg;ge;jd;id jq;fplh tz;zk; nra;Ak; 
- gjpnzz; rpj;jHfs; ehb rh];j;jpuk; 
If the vatha naadi gets highly increased and scattered, then it produces  pain   
during menstruation, due to collection of menstrual excreation and causes pain  
in the low back and lower abdominal areas. At last, these all lead to infertility   
 
ŠÀÃ¢ºõ 
By sparism the temperature of skin (thatpam-cold or veppam-heat), smoothness, 
roughness, sweating, dryness, hard patches, swelling, abnormal growth of organs and 
tenderness can be felt. 
In Some Garpavaayu patients tenderness is felt over the lower abdomen and  
patient’s temperature is increased mildly. 
 
¿¡ (Tongue) 
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   It is the examination of the tongue, its colour, size, shape, coating, moisture, 
movement, ulcer, fissures, crust and also the condition of teeth and gums. In Garpavaayu 
if there is constipation , the tongue would seem to be coated. Most of the Garpavaayu 
patients  had Paleness and dryness  
 
¿¢Èõ (Colour) 
It is the examination of the colour of the skin all over body, nail bed, hair etc. 
Vali udal -       Block colour, 
Azhal udal -    Yellow or red colour, 
Iyya udal -     White or yellow 
In Garpavaayu, niram of udal depends up on the body constitution          
 
¦Á¡Æ¢ (Speech) 
“khkapNy rj;jkJ mwpaNtz;by; 
    thjNuhfprk njhdpaha; thHj;ij NgRk; 
- gjpnzz; rpj;jH ehb rh];jpuk; 
“ghHg;gJ jhd; thjNuhfp apd;wd; thHj;ij  
    gf;Ftkha;r; rkrj;j khapUf;Fk; 
fz;Zrhkp guk;giu itj;jpak; 
By examining mozhi (speech), characters, hoarseness, slurring speech, various 
disorders of speech such as dysarthria can be noted. In Garpavaayu the voice is normal. 
 
Å¢Æ¢ (Eye) 
“fhZfpd;w thj Nuhfpf;F fz;fs; 
    fUepwkha; nehe;Jkpfj; jz;zPHghAk; 
   g+Zfpd;w gpj;jNuhfpfb kQ;rs; NghypUf;fk; 
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rptg;G epwg;nghypT Njhd;Wk;” 
   -    gjpnzz; rpj;jH ehb rh];jpuk; 
Examine the colour of eye - like reddish or yellowish discoloration and characters 
like dryness and lacrimation. There may be pallor of conjunctiva due to menorrhagia.  
 
ÁÄõ (Stools) 
By examining malam, its nature, colour, quantity and presence of blood or pus 
can be noted. In Garpavaayu constipation and black colour stools with hardness will be 
present. 
“NkTk; thj KilatH nka;kyQ; 
   rPtpjhff; fUfpLQ; nrk;kpNa 
   jd;te;jphp (gjpnzz; rpj;jH ehb rh];jpuk;) 
nghUkp uj;je;jd;id kwpj;Jg; NghjkpfTk; typAz;lhq; 
FUjpNruh tapW typNghq; nfhs;Sq; fh;g;ge;jid aopf;Fk; 
tUbapLg;Gf; File;Jisf;Fk; kyj;ijkpfT kpWf;fpWf;fp 
ngUfg;gizf;F nkdg; nghpNahHNgRq; fHg;g thA tpNj 
- mfj;jpakhKdptH MAs;Ntjk; 1200     
 
¿£÷ÌÈ¢ (Urine examination) 
Siruneer should be collected in early morning; In the previous day patient should 
eat food of six tastes at regular times and sleep well over night. Then the collected urine 
should be examined with in 3¾hrs. This is quoted as  
       “«ÕóÐÁ¡Ã¢¾Óõ «Å¢§Ã¡¾Á¾¡ö 
        «ì¸ø «Ä÷¾ø «¸¡Äçý ¾Å¢÷ó¾Æü 
       ÌüÈÇÅÕó¾¢ ¯Èí¸¢ ¨Å¸¨È 
        ¬Êì¸Äºò ¾¡Å¢¦Â¸¡Ð ¦Àö 
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       ¦¾¡ÕÓÌ÷ò¾ì ¸¨ÄìÌðÀÎ ¿£Ã¢ý 
        ¿¢ÈìÌÈ¢ ¦¿öÌÈ¢ ¿¢ÕÀ¢ò¾ø ¸¼§É” 
 
                                  -º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
Siruneerin pothugunam: 
“Åó¾ ¿£÷ì¸Ã¢ ±¨¼ Á½õ Ñ¨Ã ±ïº¦ÄÉ 
        ¨Èó¾¢ÖÇÅ¨Å Â¨ÈÌÐ Ó¨È§Â” 
                             -º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
Urine sample should be examined using the following five parameters: 
1. Niram (Color), 2. Edai (Specific gravity), 3. Nurai (Froth), 4. Natram (Smell), 5. Enjal 
(Deposits).  
 
 
NEI KURI 
The urine kept on the kidney tray in sun light, on non wind condition, should be 
examined by dropping a drop of gingelly oil gently with a rod. If oil spreads like a snake 
it indicates valineer, a ring indicates azhal neer, and a float like a pearl indicates iyya neer 
and if sinks in urine indicates mukkutram. 
        “«Ã¦ÅÉ ¿£ñÊÉì§¾ Å¡¾õ” 
         “¬Æ¢ §À¡ü ÀÃÅ¢ý «ì§¾ À¢ò¾õ” 
        “Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¦¾ý¸À§Á” 
                            -º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
 
In Garpavaayu patients, oil spreading like snake indicates Vali neer. Pattern of oil 
spreading is slow. 
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ÁÕòÐÅõ (LINE OF TREATMENT)    
 
The main object of treatment is to bring down the deranged mukkutrams to natural 
equilibrium by giving pugatives, which normalises the deranged vatham which is one of 
the causes for Garpavaayu. 
 
      “§À¾¢Â¡ø Å¡¾õ ¾¡Øõ 
         Å¡ó¾¢Â¡ø À¢ò¾õ ¾¡Øõ 
         «ïºÉò¾¡ø ¸Àõ ¾¡Øõ” 
                                            -º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
 
 
  Accordingly the author gives purgation to all patients depending upon  their body 
condition. The author has selected trial drugs Kalinga thylam (15ml at early morning on  
3 days of menstruation along with neeragaram for consecutive three cycles) and Sengottai 
valladhi legium ( I gm twice a day for 48 days). 
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REVIEW OF LITERATURE – MODERN 
1. ANATOMY AND PHYSIOLOGY OF THE FEMALE   
REPRODUCTIVE SYSTEM 
The female reproductive system includes the ovaries, Fallopian tubes, uterus, 
vagina, accessory glands, and external genital organs. 
EXTERNAL GENITALIA 
The external genitalia are the accessory structures of the female reproductive 
system that are external to the vagina. They are also referred to as the vulva or 
pudendum. The external genitalia include the labia majora, mons pubis, labia minora, 
clitoris, and glands within the vestibule. 
 The clitoris is an erectile organ, similar to the male penis, that responds to sexual  
stimulation. Posterior to the clitoris, the urethra, vagina, paraurethral glands and greater 
vestibular glands open into the vestibule. 
  The vagina is a fibromuscular tube, about 10 cm long, that extends from the 
cervix of the uterus to the outside. It is located between the rectum and the urinary 
bladder. Because the vagina is tilted posteriorly as it ascends and the cervix is tilted 
anteriorly, the cervix projects into the vagina at nearly a right angle. The vagina serves as 
a passageway for menstrual flow, receives the erect penis during intercourse, and is the 
birth canal during childbirth. 
INTERNAL GENITALIA  
Uterus 
             The uterus is lined with the endometrium. The stratum functionale of the 
endometrium 
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 sloughs off during menstruation. The deeper stratum basale provides the foundation for 
rebuilding the stratum functionale 
The uterus is a muscular organ that receives the fertilized oocyte and provides an 
appropriate environment for the developing fetus. Before the first pregnancy, the uterus is 
about the size and shape of a pear, with the narrow portion directed inferiorly. After 
childbirth, the uterus is usually larger, and then regresses after menopause. 
Fallopian Tubes 
             There are two uterine tubes, also called Fallopian tubes or oviducts. There is one 
tube associated with each ovary. The end of the tube near the ovary expands to form a 
funnel-shaped infundibulum, which is surrounded by fingerlike extensions called 
fimbriae. Because there is no direct connection between the infundibulum and the ovary, 
the oocyte enters the peritoneal cavity before it enters the Fallopian tube. At the time of 
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ovulation, the fimbriae increase their activity and create currents in the peritoneal fluid 
that help propel the oocyte into the Fallopian tube. Once inside the Fallopian tube, the 
oocyte is moved along by the rhythmic beating of cilia on the epithelial lining and by 
peristaltic action of the smooth muscle in the wall of the tube. The journey through the 
 
 Fallopian tube takes about 7 days. Because the oocyte is fertile for only 24 to 48 hours, 
fertilization usually occurs in the Fallopian tube. 
 OVARIES 
             The primary female reproductive organs, or gonads, are the two ovaries. Each 
ovary is a solid, ovoid structure about the size and shape of an almond, about 3.5 cm in 
length, 2 cm wide, and 1 cm thick. The ovaries are located in shallow depressions, called 
ovarian fossae, one on each side of the uterus, in the lateral walls of the pelvic cavity. 
They are held loosely in place by peritoneal ligaments. 
Structure 
             The ovaries are covered on the outside by a layer of simple cuboidal epithelium 
called germinal (ovarian) epithelium. This is actually the visceral peritoneum that 
envelops the ovaries. Underneath this layer there is a dense connective tissue capsule, the 
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tunica albuginea. The substance of the ovaries is distinctly divided into an outer cortex 
and an inner medulla. The cortex appears more dense and granular due to the presence of 
numerous ovarian follicles in various stages of development. Each of the follicles 
contains an oocyte, a female germ cell. The medulla is loose connective tissue with 
abundant blood vessels, lymphatic vessels, and nerve fibers. 
Oogenesis 
            Female sex cells, or gametes, develop in the ovaries by a form of meiosis called 
oogenesis. The sequence of events in oogenesis is similar to the sequence in 
spermatogenesis, but the timing and final result are different. Early in fetal development, 
primitive germ cells in the ovaries differentiate into oogonia. These divide rapidly to 
form thousands of cells, still called oogonia, which have a full complement of 46 (23 
pairs) chromosomes. Oogonia then enter a growth phase, enlarge, and become primary 
oocytes. The diploid (46 chromosomes) primary oocytes replicate their DNA and begin 
the first meiotic division, but the process stops in prophase and the cells remain in this 
suspended state until puberty. Many of the primary oocytes degenerate before birth, but 
even with this decline, the two ovaries together contain approximately 700,000 oocytes at 
birth. This is the lifetime supply, and no more will develop. This is quite different than 
the male in which spermatogonia and primary spermatocytes continue to be produced 
throughout the reproductive lifetime. By puberty the number of primary oocytes has 
further declined to about 400,000. 
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             Beginning at puberty, under the influence of follicle-stimulating hormone, 
several primary oocytes start to grow again each month. One of the primary oocytes 
seems to outgrow the others and it resumes meiosis I. The other cells degenerate. The 
large cell undergoes an unequal division so that nearly all the cytoplasm, organelles, and 
half the chromosomes go to one cell, which becomes a secondary oocyte. The remaining 
half of the chromosomes go to a smaller cell called the first polar body. The secondary 
oocyte begins the second meiotic division, but the process stops in metaphase. At this 
point ovulation occurs. If fertilization occurs, meiosis II continues. Again this is an 
unequal division with all of the cytoplasm going to the ovum, which has 23 single-
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stranded chromosome. The smaller cell from this division is a second polar body. The 
first polar body also usually divides in meiosis I to produce two even smaller polar 
bodies. If fertilization does not occur, the second meiotic division is never completed and 
the secondary oocyte degenerates. Here again there are obvious differences between the 
male and female. In spermatogenesis, four functional sperm develop from each primary 
spermatocyte. In oogenesis, only one functional fertilizable cell develops from a primary 
oocyte. The other three cells are polar bodies and they degenerate. 
 
Ovarian Follicle Development 
            An ovarian follicle consists of a developing oocyte surrounded by one or more 
layers of cells called follicular cells. At the same time that the oocyte is progressing 
through meiosis, corresponding changes are taking place in the follicular cells. Primordial 
follicles, which consist of a primary oocyte surrounded by a single layer of flattened 
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cells, develop in the fetus and are the stage that is present in the ovaries at birth and 
throughout childhood. 
             Beginning at puberty follicle-stimulating hormone stimulates changes in the 
primordial follicles. The follicular cells become cuboidal, the primary oocyte enlarges, 
and it is now a primary follicle. The follicles continue to grow under the influence of 
follicle-stimulating hormone, and the follicular cells proliferate to form several layers of 
granulose cells around the primary oocyte. Most of these primary follicles degenerate 
along with the primary oocytes within them, but usually one continues to develop each 
month. The granulosa cells start secreting estrogen and a cavity, or antrum, forms within 
the follicle. When the antrum starts to develop, the follicle becomes a secondary follicle. 
The granulose cells also secrete a glycoprotein substance that forms a clear membrane, 
the zona pellucida, around the oocyte. After about 10 days of growth the follicle is a 
mature vesicular (graafian) follicle, which forms a "blister" on the surface of the ovary 
and contains a secondary oocyte ready for ovulation. 
Ovulation  
             Ovulation, prompted by luteinizing hormone from the anterior pituitary, occurs 
when the mature follicle at the surface of the ovary ruptures and releases the secondary 
oocyte into the peritoneal cavity. The ovulated secondary oocyte, ready for fertilization is 
still surrounded by the zona pellucida and a few layers of cells called the corona radiata. 
If it is not fertilized, the secondary oocyte degenerates in a couple of days. If a sperm 
passes through the corona radiata and zona pellucida and enters the cytoplasm of the 
secondary oocyte, the second meiotic division resumes to form a polar body and a mature 
ovum
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  After ovulation and in response to luteinizing hormone, the portion of the follicle 
that remains in the ovary enlarges and is transformed into a corpus luteum. The corpus 
luteum is a glandular structure that secretes progesterone and some estrogens. Its fate 
depends on whether fertilization occurs. If fertilization does not take place, the corpus 
luteum remains functional for about 10 days then it begins to degenerate into a corpus 
albicans, which is primarily scar tissue, and its hormone output ceases. If fertilization 
occurs, the corpus luteum persists and continues its hormone functions until the placenta 
develops sufficiently to secrete the necessary hormones. Again, the corpus luteum 
ultimately degenerates into corpus albicans, but it remains functional for a longer period 
of time. 
Reproductive cycle 
An 'ovarian cycle' occurs in a woman at the same time as the menstrual cycle. 
The term 'menstrual cycle' refers specifically to the changes that occur in the uterus, 
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whereas the term 'ovarian cycle' refers specifically to the changes that occur in the 
ovaries. To ensure that follicular growth and ovulation (ovarian cycle) are synchronised 
with uterine preparation (menstrual cycle) for possible embryonic implantation, the two 
cycles are coordinated together by five hormones. This forms the 'reproductive cycle'. 
The hormones involved are the following: 
¾  Gonadotropin-releasing hormone (GnRH) secreted from the      
hypothalamus  
¾  Follicle-stimulating hormone (FSH (a gonadotropin)) secreted 
from the anterior pituitary gland  
¾ Luteinizing hormone (LH (a gonadotropin)) secreted from the 
anterior pituitary gland. 
¾ Oestrogens (closely related family of female sex hormones) 
secreted by the ovaries. 
¾ Progesterone (female sex hormone) secreted by the ovaries. 
The Menstural cycle 
             The menstrual cycle consists of three phases:  
¾ The menstrual flow phase commences at Day 1 and continues for 
these first few days, thus the thickened endometrium is lost.  
¾ This is then followed by the proliferative phase, whereby the 
endometrium is gradually built up again. 
¾ The secretory phase follows over the course of the next fourteen 
days. Here, the endometrium continues to thicken and become 
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more vascularized as well as developing glands which secrete a 
glycogen-rich fluid.  
At this stage, there are two possibilities. If the embryo has implanted itself into the 
uterine lining, pregnancy will ensue. If it has not, the cycle has ended and another will 
begin. 
The Ovarian cycle 
            The Ovarian cycle also consists of three phases:  
¾ During the follicular phase several follicles in the ovary begin to 
grow. The egg cell enlarges and the coat of follicle cells becomes 
multilayered. 
One of these follicles goes on to enlarge and mature further whilst 
the others disintegrate. The maturing follicle develops an internal 
fluid-filled cavity and grows very large, forming a bulge near the 
surface of the ovary. 
¾ Ovulation then occurs. 
The ovulatory phase is where the follicle and the adjacent wall of 
the ovary rupture resulting in the egg cell's release from the ovary. 
The follicular remains in the ovary are transformed into an 
endocrine tissue called the 'corpus luteum'. 
¾ The luteal phase follows whereby the corpus luteum secretes 
oestrogen and progesterone. 
The cycle then recommences unless pregnancy has ensued. 
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Cycles and Hormones Relationship. 
STAGE 1   
The reproductive cycle begins with the menstrual flow phase of the menstrual 
cycle. This coincides with the follicular phase of the ovarian cycle which, in turn, 
marks the beginning of the proliferative phase of the menstrual cycle. 
¾ Levels of Oestrogen and Progesterone are low as pregnancy has 
not occurred. This causes the arteries in the uterine lining to spasm, 
thus the endometrium is deprived of blood. Disintegration of the 
endometrium results in menstruation. 
¾ This low steroid hormone level results in a decline in their 
inhibitory effect on GnRH accompanies newly developing follicles 
in the ovaries 
¾ GnRH is secreted from the hypothalamus.  
¾ This, in turn, stimulates the anterior pituitary to secrete small 
amounts of FSH and LH . 
¾ There are only FSH specific receptors on cells of the immature 
ovarian follicles in the ovaries at this stage; FSH acts on these 
receptors by stimulating follicular growth. 
¾ As these follicles begin to grow, their cells secrete a small amount 
of Oestrogen which inhibits further FSH and LH secretion during 
the rest of the follicular phase. 
¾ It also stimulates endothelial thickening (proliferation) in the 
uterus. 
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¾ The uterus is thus prepared for a possible implanting embryo prior 
to ovulation. 
STAGE 2  
 The ovulatory phase of the ovarian cycle now occurs. 
¾ At a certain point of growth the follicle's secretion of Oestrogen 
suddenly rises steeply resulting in the stimulation of the 
hypothalamus to secrete GnRH and thus the subsequent release of 
FSH and LH. 
¾ Increased sensitivity of LH releasing mechanisms in the pituitary 
to GnRH, thus there is a more dramatic release of LH than FSH. 
¾ The follicles have now developed LH specific receptors. 
¾ This LH increase induces the final maturation of the follicle and 
ovulation follows a day after the LH surge.  
STAGE 3 
The luteal phase of the ovarian cycle, coordinated with the secretory phase of the 
menstrual cycle follows. 
¾ Following ovulation, high LH levels also stimulate the follicular 
tissue's development into a 'corpus luteum', reaching its maximum 
development about 10 days after ovulation. (LH is named after this 
luteinising function).  
¾ LH stimulates the corpus luteum to secrete Oestrogen and 
Progesterone.  
 32
¾ These hormones stimulate continued endometrial maintenance by 
means of enlarging arteries supplying blood to the uterine lining 
and enabling the growth of endometrial glands that secrete an 
embryonic sustaining nutrient fluid before it implants in the lining 
itself. 
¾ The rising levels of Oestrogen and Progesterone also inhibit the 
hypothalamic and pituitary hormone release.  
¾ When LH levels become too low, however, the corpus luteum 
disintegrates. Thus, if pregnancy has not ensued, Oestrogen and 
Progesterone levels fall. 
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                                            Female Reproduction 
1). Fetus 
Fetal cortical (outer) region of the ovaries 
 
primordial follicle (primary follicles) with primary oocytes 
       
Meiosis I begins: (duplication & crossing over occur) 
   
Meiosis I  stops  
       
2).  Childhood 
 
3). Puberty  
 
Primary oocyte continues the last stages of meiosis. 
Meiosis results in a small polar body and a secondary oocyte 
Ovulation occurs  
The secondary oocyte is ovulated and follicle undergoes changes 
(it has not completed meiosis) 
 
4). If fertilization occurs 
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If it is fertilized Meiosis II will continue. 
The secondary oocyte will under go Meiosis II before the 
chromosomes of the male can join to the chromosomes of the 
female. 
 
The result will be an ovum and a polar body. 
 
The ovum can than be fertilized.  
Polar bodies only contain DNA the secondary oocyte maintains all of the cytoplasm and 
organelles 
 
Ovarian Cycle 
Ovarian cycle: 
    average 28 days. 
Several follicles will start this process at the same time.  
Stage 
Follicular phase: Day 1 to 14 
primordial follicle   primary follicle 
primary follicle    secondary follicle 
Theca follici develop granulosa cells and theca follici produce 
estrogen 
Zona pellucida forms  secondary follicle      vesticular follicle 
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bulges from the ovary 
The primary oocyte finishes meiosis I (that was started as a fetus) 
and it becomes the secondary oocyte with a polar body. 
Ovulation:  
Day 14 
Luteal phase: 
    Day 14 to 28. 
Corpus luteum acts as an endocrine gland producing: 
   Progesterone and estrogen 
 
Uterine Cycle 
Changes that the endometrium undergoes 
Uterine (Menstrual) Cycle  
Wall of the uterus  
   Endometrium:  inner 
   Myometrium:   middle 
   Perimetrium:   outer 
  Stages 
Menstrual phase (Days 1-5) 
Proliferative phase (Days 6-14) 
Secretory Phase (Days 15-28) 
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Hormonal Control of Female Reproduction 
Starting on Day 1: 
Uterine wall detaches: 
Estrogen at lowest level but: 
Hypothalamus: 
GnRH 
Anterior Pituitary: 
 FSH  LH 
Ovary responds  
Follicle growth 
Day 5 
Ovary  
 Estrogen 
Day 6-14 
Uterus:  generating new basal layer. 
Ovary: Follicle is  continues to grow 
 Estrogen &  Inhibin 
Anterior Pituitary responds by 
 FSH &  LH release but 
  synthesis & storage of FSH & LH 
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Day 14 (ovulation) 
 High estrogen in the blood reach a critical level overriding any effect 
that inhibin has. 
Anterior Pituitary  FSH &  LH (releasing the built up supply) 
Ovary completes first meiotic division. 
 LH level results in ovulation 
Day 14 to Day 28 
 LH creates corpus luteum 
Corpus luteum :   Estrogen  Progesterone 
Uterus enters secretory phase 
 Estrogen  Progesterone negatively feedbacks   LH & FSH 
 LH causes  corpus luteum & estrogen &  progesterone  
endometrium sloughs off 
 Estrogen takes the block off LH & FSH. 
The cycle starts again. 
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2. POLY CYSTIC OVARIAN DISEASE. 
Background 
In 1935 Stein and Leventhal were first to recognize an association between the 
presence of polycystic ovaries and signs of hirsutism and amenorrhea (eg, 
oligomenorrhea, obesity). Patients diagnosed with Stein-Leventhal syndrome underwent 
successful wedge resection of the ovaries, their menstrual cycles became regular, and 
they were able to conceive. As a consequence, a primary ovarian defect was thought to be 
the main culprit, and the disorder came to be known as polycystic ovarian disease. 
Further biochemical, clinical, and endocrinologic studies revealed an array of underlying 
abnormalities; hence, the condition is now referred to as polycystic ovary syndrome 
(PCOS), though it may occur in patients without ovarian cysts. 
Frequency 
PCOS is one of the most common endocrine disorders of patient in the 
reproductive age group, with a prevalence of 4-12%. About one in five patient have 
PCOS, and generally they present no problems.  
Age 
PCOS affects mostly patients of reproductive age. 
Alternate names:  
Stein-Leventhal Syndrome, Hyperandrogenic Chronic Anovulation, solcrocystic 
ovarian disease, polycystic ovaries, polycystic ovarian disease (PCOD), polycystic 
ovarian syndrome(PCOS). 
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Definition:  
Patients suffering from polycystic ovarian disease ( PCOD ) have multiple small 
cysts in their ovaries ( the word poly means many). These cysts occur when the regular 
changes of a normal menstrual cycle are disrupted. The ovary is enlarged; and produces 
excessive amounts of androgen and estrogenic hormones. This excess, along with the 
absence of ovulation, may cause infertility.  
On the scan a polycystic ovary is larger than normal with a ring of many cysts around the 
edge. The cysts are follicles, some are immature but contain an egg, and others are 
empty. A polycystic ovary contains at least ten cysts just below the surface, and although 
each cyst only measures between two and eight millimetres, together they make the ovary 
enlarged. The covering of the ovary (the capsule) thickens, which makes release of the 
egg difficult. 
Causes:  
            Although the cause of PCO is not fully understood, there are a few theories 
suggesting that problems with estrogen production and hypothalamic-ovarian feedback 
may be responsible. Ovarian function will not proceed normally under reduced amounts 
of pituitary hormones, however, an increase in the amount of follicle-stimulating 
hormone (FSH) which is one of the hormones normally produced by the pituitary gland, 
is frequently successful in stimulating the underdeveloped ova to mature and be released 
from the ovary. 
  PCOD has a significant hereditary component, and is often transmitted from 
mother to daughter. Polycystic ovary emerges when a state of anovulation persists for a 
length of time. Patients with PCO have persistently elevated levels of androgens and 
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estrogens, which set up a vicious cycle. Obesity can aggravate PCOD because fatty 
tissues are hormonally active and they produce estrogen which disrupts ovulation. 
Overactive adrenal glands can also produce excess androgens, and these may also 
contribute to PCOD. These patients also have insulin resistance (high levels of insulin in 
their blood, because their cells do not respond normally to insulin). 
                                        
 The self-perpetuating vicious cycle of elevated levels of androgens and estrogens in PCOD 
 
Occult PCOD  
Occult PCOD means the patients with thin built, regular periods, no hirsutism and 
normal looking ovaries on ultrasound, but still have PCOD. This problem is detected only 
when these patients are super ovulated, at which time they over-respond by producing a 
large number of follicles. 
Interestingly, many of these patients present with recurrent pregnancy loss ( recurrent 
miscarriages) , and often their doctor does not make the correct diagnosis for them 
 
Pathophysiology 
Patients with PCOS have abnormalities in the metabolism of androgens and 
estrogen and in the control of androgen production. High serum concentrations of 
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androgenic hormones, such as testosterone, androstenedione, and dehydroepiandrosterone 
sulfate (DHEA-S), may be encountered in these patients. However, individual variation is 
considerable, and particular patients might have normal androgen levels. 
PCOS is also associated with peripheral insulin resistance and hyperinsulinemia, and 
obesity amplifies the degree of both abnormalities. Insulin resistance in PCOS can be 
secondary to a post binding defect in insulin receptor signaling pathways, and elevated 
insulin levels may have gonadotropin-augmenting effects on ovarian function. 
A proposed mechanism for anovulation and elevated androgen levels suggests that, under 
the increased stimulatory effect of luteinizing hormone (LH) secreted by the anterior 
pituitary, stimulation of the ovarian theca cells is increased. In turn, these cells increase 
the production of androgens (eg, testosterone, androstenedione). Because of a decreased 
level of follicle-stimulating hormone (FSH) relative to LH, the ovarian granulosa cells 
cannot aromatize the androgens to estrogens, and this inability leads to decreased 
estrogen levels and consequent anovulation. Growth hormone (GH) and insulin-like 
growth factor-1 (IGF-1) may also augmenting effect on ovarian function. 
Hyperinsulinemia is also responsible for dyslipidemia and for elevated levels of 
plasminogen activator inhibitor-1 (PAI-1) in patients with PCOS. An elevated PAI-1 
level is a risk factor for intravascular thrombosis. 
Polycystic ovaries are enlarged bilaterally and have a smooth thickened capsule that is 
avascular. On cut sections, subcapsular follicles in various stages of atresia are seen in the 
peripheral part of the ovary. The most striking ovarian feature of PCOS is hyperplasia of 
the theca stromal cells surrounding arrested follicles. On microscopic examination, 
luteinized theca cells are seen. 
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                            A schematic, comparing a polycystic ovary with a normal ovary. 
 
Clinical Features 
Menstrual periods, abnormal, irregular, or oligomenorrhea, amenorrhea, usually 
(but not always) after having one or more normal menstrual periods during puberty 
(secondary amenorrhea), obesity, infertility,  increased hair growth (hirsutism), 
aggravation of acne, unusual growth and distribution of body hair in a male, pattern 
(virilization)  
Polycystic ovarian disease (PCOD) is currently considered as possibly the most 
frequent cause of female infertility. It is also closely associated with syndrome XX, 
which, in turn, is closely linked with premature and excessive mortality 
 
Irregular or absent periods 
Nine or fewer menstrual cycles per year may be a sign of PCOS. Bleeding 
may be heavier than normal. Most patients with PCOS do not ovulate because 
their follicles never ripen enough to reach the ovary's surface and burst. Some 
patients ovulate occasionally. So they don’t have any periods, or they may be very 
irregular and scanty. Patients with PCOS may start their periods late and they may 
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also always have irregular cycles. On the other hand some patients may have 
heavy irregular bleeding because of the poor hormone control. The menstrual 
irregularities in PCOS usually manifest around the time of menarche 
Infertility 
PCOS patients will only be ovulating occasionally or not at all, so getting 
pregnant without treatment may be difficult or impossible. Many patients do not 
go to their doctors with irregular periods until they start trying to have a baby. 
patients with PCOS may have fewer children than they had planned 
Hirsutism  
Hirsutism means excess hair, which can be a difficult symptom for many 
patients. Many patients with PCOS experience unwanted hair on their face, chest, 
abdomen, arms and legs. Hair growth might be quite thick and noticeable, 
especially if patients have dark hair. Some patients also notice a slight thinning of 
their head hair. 
For most patients with PCOS, hair in the mustache and beard areas 
becomes heavier and darker. This symptom is caused by high levels of male 
hormones (androgens), as are thinning hair and acne.  
Thinning hair  
Just as heavier hair growth is possible, scalp hair thinning may be present. 
This is caused by higher levels of androgens.  
Acne  
Acne (pimples and oily skin) can also bother patients with PCOS. The 
acne is usually found around the face (especially along the jaw line), chest, and 
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back. Many patients who go to their doctor with adult acne find they have 
polycystic ovaries. 
Weight gain  
Obesity is present in nearly half of all patients with PCOS. 
Many patients with PCOS gain weight around their middles taking on an apple 
shape rather than a pear shape. Such weight gain is linked with problems with the 
proper use of glucose and insulin in the body. If patients put on a lot of weight, 
then they may be at increased risk of developing heart disease, high blood 
pressure or diabetes later in life. 
Other skin problems  
Skin tags, thick lumps of skin can form and usually are found in the 
armpits or neck. These can easily be removed. Darkening and thickening of the 
skin also can occur around the neck, groin, underarms, or skin folds. This 
condition, called acanthosis nigricans, is a sign of an insulin abnormality.  
 
 
Depression and anxiety  
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Because of the nature of many of these symptoms, patients may find 
themselves more anxious or depressed by their appearance, or by their inability to 
become pregnant.  
Miscarriage 
There may be an increased risk of miscarriage for patients who do become 
pregnant. 
Pelvic discomfort 
Some patients with PCOS feel occasional discomfort in their abdomen. 
Diabetes mellitus 
Approximately 10% of patients with PCOS have type 2 diabetes mellitus, 
and 30-40% of patients with PCOS have impaired glucose tolerance by the age of 
40 years. 
A few patients may also have increased muscle mass, deepening voice, 
and/or clitoromegaly due to excessive androgens. 
Sleep apnea: 
 Many patients with PCOS have obstructive sleep apnea syndrome. These 
patients have excessive daytime somnolence and have apnea/hypopnea episodes 
during sleep.   
        
Complications  
PCOS may put patients at risk for diabetes, heart disease, and cancer of the uterus.  
Cardiovascular and cerebrovascular disease: 
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 Evidence suggests that these patients might be at increased for 
cardiovascular disease and cerebrovascular disease. Patients with high insulin 
levels, as in PCOS, often have low levels of HDL cholesterol and high levels of 
other fats, including triglycerides. These factors are known to increase the risk of 
heart attack or stroke later in life. Patients with PCOS also can have elevated bad 
cholesterol (LDL) levels. 
Type 2 diabetes mellitus:  
Patients with PCOS have an increased risk of developing diabetes 
mellitus. Patients who are obese should be screened for glucose intolerance with 
OGTT.  
Endometrial carcinoma: 
Patients with PCOS are at an increased risk for endometrial hyperplasia 
and carcinoma. The chronic anovulation in PCOS leads to constant endometrial 
stimulation with estrogen and without progesterone and increases the risk of 
endometrial hyperplasia and carcinoma. 
 
Differential diagnosis 
Acromegaly 
Cushing Syndrome 
Hyperprolactinemia 
Hypothyroidism  
Other Problems to be considered 
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Ovarian hyperthecosis  
Congenital adrenal hyperplasia (late-onset)  
Androgen-producing tumors of the ovary and adrenals  
Drugs (eg, danazol, androgenic progestins) 
Ovarian cysts 
An ovarian cyst is a growth or swelling on, or inside, the ovary. It may be solid, or filled 
with fluid. Cysts may grow inside the ovary or they may be attached by a stem to the 
outside. (The stem is sometimes called a pedicle). 
Types of ovarian cysts 
Functional cysts 
                  These are the most common type of cysts. They occur as a variation 
            of the normal function of the ovaries. 
During patients monthly cycle one of the follicles may not release 
its egg or it may not shrink after ovulation. The follicle enlarges and fills 
with fluid. Follicular cysts can last for four to six weeks and grow to 5 to 6 
cm in diameter. They usually go away by themselves. 
A less common type of functional cyst can form in the corpus 
luteum. Corpus luteum cysts form when the corpus luteum fills with fluid 
instead of breaking down as it should. Corpus luteum cysts can become 
larger than follicular cysts and so may cause pelvic discomfort. Usually 
corpus luteum cysts go away over two or three menstrual cycles, but 
occasionally bleeding in the cyst can cause a strong abdominal pain 
similar to that of an ectopic pregnancy. 
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Dermoid cysts 
Dermoid cysts originate in the ovarian cells that form into different 
tissues as the fertilized egg develops. These cysts can grow quite large up 
to 15 cm in diameter and may contain hair, bone, teeth and cartilage. In 
about 12% of cases dermoid cysts may be present on both ovaries. Large 
cysts are more prone to torsion, where the cyst twists on its stem, cutting 
off the blood supply and causing intense pain.  
Serous and mucinous cystadenomas 
These can grow to be very big and heavy, and may even weigh 
several stone. Serous cystadenomas are filled with a watery liquid, and the 
mucinous ones with a thicker sticky fluid. Both types often grow outside 
the ovary, attached by stems. They are not always benign and should be 
removed as quickly as possible. 
Endometriomas 
Up to 60% of patients with endometriosis have endometriomas. 
These are cysts lined with endometrial cells similar to those lining the 
womb. These cells bleed during menstruation. The old blood in the cyst 
gives them a 'chocolate' appearance.  
Solid Ovarian Tumours 
Functional tumours (Ovarian stromal tumours) 
             Functional tumours are completely different and much rarer than 
functional cysts. They are called either masculinising or feminising 
because they produce either male or female hormones. Masculinising 
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tumours tend to occur in patients in their 20s and 30s. Feminising tumours 
can occur at any age, even before puberty. They are usually benign, but 
need to be removed surgically because of the small risk that they are not 
benign. 
Fibromas 
             These ovarian cysts are usually solid although they sometimes 
have fluid parts and may contain some bone. In some patients they 
produce oestrogen.  
Brenner tumours 
              These are rare, solid ovarian cysts that are most commonly found 
in patients over 40. They are usually quite small and always benign. 
Investigation 
Blood tests.  
Estriol – serum  
Elevated LH levels (serum LH >10 IU/l). 
Low or normal FSH levels (if they are normal, they are still probably 
below the threshold level required for normal follicle development). 
Elevated LH/FSH ratio (>2:1 or 3:1). 
Elevated androgens/testosterone. 
Urine tests. 
17-ketosteriods (may be elevated)     
   Estriol - urine 
 
 51
         
Ultra sonogram  
This diagnosis can be confirmed by vaginal ultrasound, which 
shows that both the ovaries are enlarged; the bright central stroma is 
increased ; Polycystic ovaries are defined as 12 or more follicles in at least 
1 ovary measuring 2-9 mm in diameter or a total ovarian volume of >10 
cm3. These cysts are usually arranged in the form of a necklace along the 
periphery of the ovary and resembling a "pearl necklace".  
Laparoscopy 
Ovarian biopsy 
 
Treatment in modern medicine   
Medications used to treat the symptoms of Stein-Leventhal include oral 
contraceptives, Metformine, Testolactone, and Clomiphene Citrate (chlomid).  
Treatment with Clomiphene induces the pituitary gland to produce more FSH 
which in turn stimulates maturity and release of the ova. 
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A "wedge resection" of the ovaries may be used to remove cysts and still allow 
contraception (since ova don't mature) 
Finally, weight reduction, which may be very difficult, is very important. 
Maintaining general good health and eliminating the complications of obesity is essential. 
 Increasing physical activity is an important step in losing weight. Aerobic activities such 
as walking, jogging or swimming are advised. 
Adverse  effect of Modern treatment 
Clomiphene may cause side effects. They are, flushing (feeling of warmth), 
stomach upset, vomiting, heaviness of the breast, headache, abnormal vaginal bleeding. 
Some side effects may be serious; they are blurred vision, visual spots or flashes, 
double vision, abdominal pain, weight gain, shortness of breath.  
Long-term use of clomiphene may increase the risk of ovarian cancer. 
Clomiphene should not be used for more than about six cycles.  
Management of PCOD 
Monitoring the health is important. Obese patients with PCOS should have at 
least one oral glucose tolerance test to check the risk of diabetes and also patient should 
check for blood pressure and LDL (bad) cholesterol, HDL (good) cholesterol, and 
triglyercide levels.  This is especially important if the patients are obese.  
The following changes can help to improve the body's response to extra insulin and help 
to reduce the risk of diabetes, heart disease, and stroke  
Try to stay on a healthy diet with adequate amounts of protein.  
Add whole grains, fruits, and vegetables to patients diet; and 
Exercise regularly to keep patients weight in check.  
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       MATERIALS AND METHODS 
 
 POPULATION & SAMPLE  
The population consists of PCOD patients [Who show sympyoms of 
Garpaavayu and multiple cysts or enlarged ovary in their ultrasonogram (USG) 
report ] satisfying the inclusion and exclusion criteria mentioned below. 
           The sample consists of PCOD patients attending the OPD of Ayothidoss 
Pandithar Hospital of the National Institute of Siddha,   Chennai-47. 
INCLUSION CRITERIA 
                                                1. Age 15 -45 years    
      2. Willing to attend IP/OP treatment                                                                     
3. Willing to undergo purgation as a preparatory part of 
treatment.  
EXCLUSION CRITERIA 
1. Cardiac disease                                                                                        
2. Pregnancy and lactation 
                                                3. Hypertension 
                                                4. Peptic ulcer   
  
WITHDRAWAL CRITERIA 
During trial treatment, if the patient develops any of the following 
symptoms, 
   she will be withdrawn from the study.  
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                                                1. Severe abdominal pain.                                                                                    
2. Heavy menorrhagia.                                                      
3. Any other acute illness. 
TRIAL DRUG AND DURATION 
 Kalingadhi thylam – 15 ml in empty stomach for first three 
mornings from the starting day of menstruation along with 
neeragaram for 3 consecutive cycles. 
Sengottai valladhi legium – 2 g twice a day for 48 days   
Trial treatment period is 3 cycles. 
 SAMPLE SIZE 
                       The trial size is 30 patients. 
 
TESTS AND ASSESSMENT 
                (a) CLINICAL  ASSESSMENT 
Irregular menstruation, amenorrhea, oligomenorrhea, 
dysmenorrhea, infertility, spontaneous abortions, obesity, 
hirsuitism, constipation.     
   
        (b) ASSESSMENT BY INVESTIGATION 
                                   BLOOD 
                                      TC (cells / cu mm), DC (%), ESR (mm), Hb (g %), 
                   Blood sugar (mg %).                 
             URINE    
Albumin, Sugar, Deposit, (Neerkuri, Neikuri),  
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            ULTRASONOGRAM  
Abdomen and Pelvis 
    (C) ASSESSMENT BY SIDDHA SYSTEM 
Naadi. Sparisam, Naa, Niram ,Mozhi, Vizhi, Malam, 
Moothiram (Neer kuri and Nei kuri). 
   CONDUCT 
                        Patients satisfying inclusion and exclusion criteria are selected for 
the study. Informed consent will be obtained from the patients. 
The trial patients will be issued drugs for 15 days at a time. They will be 
instructed to come for next visit after 15 days. They will also be asked to bring 
back the unconsumed drug in their next visit and return the same. 
  FORMS 
                  Form -1 
                        Selection proforma – used before admission to the trial 
Form -2 
                        Assessment proforma – used during their visits once in 15 days 
       ANALYSIS 
Paired t - test - before and after treatment meant for 
objective parameters. 
Paired chi - squared test - before and after treatment 
proportionate for signs and symptoms.                                                                             
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      OBSERVATION AND RESULTS 
 
                                                                                                        
DISTRIBUTION OF CASES BY AGE 
                 
Table No: 1   
                                       
Age Group  No of cases  Percentage 
15  to 25 17 56 
26 to 35 12 40 
36 to 45 1 4 
Total 30 100 
Among the 30 cases of this study 56% of cases were in the age group between 15 
to 25 yrs.  40% of cases were in the age group between 26 to 35yrs.  
 
DISTRIBUTION OF CASES BY IMPROVEMENT
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36 - 45 Years
4%
15 - 25yr
26 - 35yr
36 - 45yr
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DISTRIBUTION OF CASES BY FOOD HABIT 
Table  No. 2  
                                             
Food Habit No. of. Cases (out of 30) Percentage 
Vegetarian 5 17 
Non Vegetarian 25 83 
Total 30 100 
Out of 30 cases, 17% of cases were Vegetarian and 83% of cases were Non 
Vegetarian.    
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DISTRIBUTION OF CASES BY MARITAL STATUS 
 
Table No : 3   
 
Marital Status No. of. Cases  (out of 30) Percentage 
Married 
 
Nulli para 10 33 
Multi paara 3 10 
Unmarried  17 57 
 
Out of 30 cases, 43% of cases were Married and 57% of cases were Unmarried. 
In this 33% of cases are Nulli para and 10% were Multi para.    
 
DISTRIBUTION OF CASES BY THINAI 
Table  No. 4  
    
Thinai No. of. Cases  affected  Percentage 
Kurinji 2 7 
Mullai 0 0 
Marutham 8 27 
Neithal 20 66 
Palai 0 0 
Total 30 100 
 
Out of 30 cases, 66% of cases were Neithal Thinai and 27% of cases were in Marutham. 
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PHYSICAL BUILT 
Table  No. 5 
   
Physical built No of cases Percentage 
Lean 3 10 
Normal 7 24 
obese 20 66 
Total 30 100 
Out of 30 cases, 66% of cases were Obese and 24% of cases were in Normal. 
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DISTRIBUTION OF CASES BY YAKKAI 
Table  No. 6  
 
Yakkai               No. of. Cases  Percentage 
Vatham      18 60 
Vatha pitham 6 20 
Pitha vatham 3 10 
Pitha kabam 3 10 
Total 30 100 
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Out of 30 cases, 60% of cases were Vatha udal,  20% of cases were vatha pitha  udal. 
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UYIR THATHUKKAL 
Table  No. 7 
                                                      
Uyir Thathukkal No. of. Cases affected (out of 30) Percentage
Vali  Pranan  0 0 
Abanan  30 100 
Samanan  22 73 
Uthanan     0 0 
Viyanan  24 79 
Naahan 0 0 
Koorman   0 0 
Kiruharan    0 0 
Devathathan  0 0 
Dhananjeyan   - - 
Azhal Analam 22  73 
Ranjagam 18 59 
Alosagam  0 0 
Prasagam                           10 33 
Saathaham  5 17 
Iyya
 
 
 
Avalambagam 5 17 
Kilethagam  22 73 
Pothagam 0 0 
Tharpagam  0 0 
Santhigam  5 17 
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In types of Vali, out of the 30 cases of this study,  100% of cases Abaanan 79% of 
cases viyanan and 73% of cases Samaanan were affected.  
In Azhal, out of 30 cases of this study, 73% of cases Analam, 59% of cases of 
Ranjagam are affected. In 17% of case Saathaham is affected. In 33% of cases Prasagam 
is affected.  
In Iyyam, out of 30 cases of this study, 73% of cases kilethagam is affected. 17% 
of cases, Avalambagam and Santhigam are affected.  
 
UDAL THATHUKKAL 
Table  No. 8  
 
      
Udal Thathukkal No. of. Cases affected  (out of 30) Percentage 
Saaram      22 73 
Senneer   18 59 
Oon         24 79 
Kozhuppu   24 79 
Enbu       5 17 
Moolai      0 0 
Suronitham 30 100 
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In udal thaathukkal Out of 30 cases, all of them (100%) have deranged suronitham, 79% 
of cases have deranged Oon and Kozhuppu, 59% of cases have deranged Senneer. 73% 
and 17% of cases have deranged Saaram and Enbu respectively. 
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DISTRIBUTION OF CASES BY NAADI 
                     
Table  No. 9  
  
Naadi No. of. Cases   (out of 30) Percentage 
Vali Azhal 22 73 
Azhal Vali 7 24 
Azhal Iyyam 1 3 
Total 30 100 
 
 
Among the 30 cases of this study, 73 % had  Vali Azhal naadi, 24% of cases had 
Azhal Vali naadi and 3% of cases had Azhal Iyyam naadi. 
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DISTRIBUTION OF CASES BY ENVAGAI THERVU 
 
Table  No. 10  
 
 No. of. Cases  (out 
of 30) 
Percentage 
Naa   Normal 11 37 
Veluppu 18 59 
Maapadithal 22 73 
Niram Normal 20 67 
Affected(hyperpigmentation) 10 33 
Mozhi  Urattha oli 0 0 
Sama oli 30 100 
Thazhntha oli 0 0 
Vizhi  
 
Normal 12 12 
Veluppu  18 59 
Sparisam  Miguvepam 0 0 
 Thatpam 0 0 
 Midhavepam 30 100 
Malam  Normal 8 27 
Affected (Malasikkal) 22 73 
Total 30 100 
 
Among the 30 cases of this study 59 % of cases had pale tongue and 73% of cases 
had coated tongue. In niram 33 % case had hyperpigmentation.  In Mozhi 100 % cases 
were sama oli. And in vizhi 59% of cases were pallor conjunctiva. In Sparism among 30 
cases 100% cases were normal(Mithaveppam). In Malam  73% of cases had constipation.  
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                                 DISTRIBUTION OF CASES BY NEERKURI 
Table  No. 11 
      
Neer Kuri No. of. Cases  (out of 30) Percentage 
Neer Niram Crystal clear       4 13 
Pale yellow         20 67 
Dark  yellow         6 20 
Total 30 100 
Nurai 
 
 
Present              9 30 
Absent 21 70 
Total 30 100 
Enjal 
 
Present              0 0 
Absent 30 100 
Total 30 100 
   
  
 
DISTRIBUTION OF CASES BY NEI KURI 
Table  No. 12   
 
Neer Kuri No. of. Cases  (out of 30) Percentage 
Vali 
 
4 13 
Azhal 
 
2 7 
Iyyam 
 
3 10 
Fastly spread 
 
                         2 7 
Slowly spread 
 
                        20 66 
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Among the 30 cases of this study 13% of cases were having Vali. 7% of cases 
were having Azhal. 10% of Cases were having Iyyam and 66% of cases were having 
slowly spread pattern of urine. In 7% of cases were having fastly spread pattern of urine. 
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DISTRIBUTION OF CASES BY CLINICAL SIGNS OF GARPAVAAYU 
 
Table  No. 13  
    
Clinical Sign of 
Garpavaayu 
 No. of. Cases (out of 
30) 
               Observed 
No. of. Cases (out of 
30) 
Improved 
Percentage 
Irreregular menstruation 30 28 92 
Infertility 11 1 9 
Oligomenorria 22 22 100 
Dysmenorria 24 24 100 
Menorrhagia 7 7 100 
Weight gain 24 24 100 
Hirsutism 7 0 0 
Constipation 22 22 100 
Missed abortions 1 0 0 
Anemea 18 18 100 
 
In clinical sign, out of the 30 cases, 100% of cases menstrual cycle was irregular 
and lengthy before treatment. After treatment the length of cycle were shortened in 28 
patients (92%). 2 patients with  oral contraceptive pills induced menstruation did not 
respond to this treatment. Out of 28 patients one patient is pregnant, 21 patients were 
getting regular cyclic with the lenth between 28 to 32 days ( ie normal).  
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DURATION OF FLOW 
22 cases (73%) have Oligomennoria (short duration of flow) were treated and they got 
normal duration of flow now, 7 patients (23%) with Menorrhagia were treated and they 
got normal duration of flow now. 
 
FLOW LEVEL 
7 patients(23%) with high flow level, 22 patients(73%) with low flow level were 
corrected to normal flow level. 
 
CONSTIPATION  
Among the 30 cases of this study 73% of cases have Constipation and they 
relieved their constipation during treatment. 
 
 WEIGHT GAIN   
Among the 30 cases of this study 79% of cases have weight gain. After treatment 
most of them lost their weight upto 7 kg( avg 3.5kg)  
 
PAIN 
Among the 30 cases of this study 79% of cases had Dysmennoria and they 
relieved their Dysmennoria during treatment. 
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ANEMIA. 
Among the 30 cases of this study 59% of cases had anemia and after the treatment 
all of them had improved. 
 
 
        DISTRIBUTION OF IMPROVED PERCENTAGE OF CLINICAL SIGNS IN GARPAVAAYU 
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RESULT OF CLINICAL FEATURES AFTER TREATMENT 
 
Table  No. 14     
Result No. Cases % 
 Very good improvement 14 46 
Good improvement 8 27 
Moderate imprivement 6 20 
Nil imprivement 2 7 
Total 30 100 
 
Out of the 30 cases, 46% of cases had very good improvement, 27% of cases had 
good improvement, 20% of cases had Moderate improvement and 7% of cases have nil 
improvements. The results were statistically 
significant.
DISTRIBUTION OF CASES BY IMPROVEMENT
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ULTRASONOGRAPHY REPORTS IN BEFORE AND AFTER TREATMENT 
 
S. No O P No Name Age Before treatment After treatment 
1 AH 4811 Anusia 24 Polycystic ovaries Normal study 
2 AE 3866 Priya 28 Polycystic ovaries Normal study 
3 AE 1210 Aanandhi 24 Polycystic ovaries Normal study 
4 AB 754 Sheeja 19 Polycystic ovaries Normal study 
5 AE 4196 Rajeswari 30 Polycystic ovaries Not taken 
6 AE 3059 Parameshwari 27 Polycystic ovaries Not taken 
7 AF 4152 Prema 25 Polycystic ovaries Normal study 
8 AG 8043 Rasiya baanu 22 Polycystic ovaries Normal study 
9 AF 4135  Jaba 20 Polycystic ovaries Normal study 
10 AG 9190 Jayanti 19 Polycystic ovaries Not taken 
11 AF 445 Anandhi 21 Polycystic ovaries Normal study 
12 AD 5859 Malathi 29 Polycystic ovaries Not taken 
13 AG 2553  Gayathri priya 19 Polycystic ovaries Polycystic ovaries 
14 AF 1104  Saranya 17 Polycystic ovaries Not taken 
15 AD 7553 Malarvathana 26 Polycystic ovaries Polycystic ovaries  
16 AG 4653  Tamil selvi 18 Polycystic ovaries Not taken 
17 AG 5592 Saraswathy 30 Polycystic ovaries Normal study 
18 AF 2800  Lakshmi 21 Polycystic ovaries Not taken 
19 AF3577 Chitra 25 Polycystic ovaries Polycystic ovaries 
20 AG 1271 Madeswari 29 Polycystic ovaries Not taken 
21 AG 4625 Rekha 33 Polycystic ovaries Not taken 
22 AA 6229 Vijaya rani 34 Polycystic ovaries Normal study 
23 Z1860 Vijaya 31 Polycystic ovaries Normal study 
24 AE 7129  Uma  21 Polycystic ovaries Normal study 
25 AE 554 Thirupura sundari   36 Polycystic ovaries Normal study 
26 AE 527 Kalai selvi 25 Polycystic ovaries Not taken 
27 AE 7130 Anandi 18 Polycystic ovaries Normal study 
28 AG 4622 Poornima 23 Polycystic ovaries Polycystic ovaries 
29 AG 2163 Magesh vani 30 Polycystic ovaries Not taken 
30 AE 8744 Vijaya lakshmi 32 Polycystic ovaries Gravid uterus & normal 
ovaries 
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 Out of the 30 cases, 19 Patients took ultrasonography, after treatment. Among 30 
patients, in 14 patients USG reports shows normal study, in 4 patients USG reports shows 
polycystic ovaries and one patient USG reports shows gravid uterus and normal ovaries. 
11 patients did not taken USG after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
 
 
 
 
 75
                OP.No: AB 2564  Anandi  -  Before Treatment(S.No 11) 
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          OP.No: AB 2564  Anandi  -  After Treatment (S.No 11) 
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                OP.No: AE   7129 Uma -  Before Treatment (S.No 24)  
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            OP.No: AE   7129 Uma -  After Treatment (S.No 24)   
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DISCUSSION 
¾ Approximately 1000 cases of Soothaga Noi were recorded in the out 
patient department of Ayothidoss pandithar hospital, National institute of 
siddha. Author has seen 100 cases of Soothaga Noi in which author 
selected 30 cases, with the clinical symptoms of Garpavaayu for the 
study. 
¾ Garpavaayu is a specific type of disease with the symptoms of  Mensrual 
disturbances i.e Amenorrhea, Oligomenorrhea followed by Menorrhagia, 
Dysmenorrhea, Infertility, missed abortions, low back pain, Constipation 
and Obesity. 
¾ So many Siddhars described about the Soothaga noi. In which Siddhar 
Agasthiyar mentions about the Garpavaayu and its symptoms which is 
more similar to that of PCOD in modern medicine.  
¾ Among the 30 patients admitted in the Out patient and Inpatient 
department of Ayodidoss Pandithar Hospital, National institute of 
Siddha. All the patients were treated through out all the seasons.  
¾ In the present study comprising 30 patients, all were between the ages of 
15 to 45 years. Most of them are in the age of 15 to 35 years, very few in 
35 to 45yrs.  
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¾ In Garpavaayu majority of cases were having Maapadithal in the tongue.  
The colours of the tongue were Velluppu (pallor).  
¾ Most cases have Sama oli. In Most of the cases vizhiyin niram is Vellupu  
¾ Most cases have Mitha veppam. In Garpavaayu most cases have 
Malasikkal.  
¾ Most Cases have showed Manjal niram in urine. The Nei kuri of 
Garpavaayu shows mostly vatham and sathiya Nei kuri i.e slowly 
spreading in nature. 
¾ In Garpavaayu  Eruvaai and karuvaai are affected  
¾ In the sub types of Vali, Abanan, Samaanan, Viyaanan and are affected.  
¾ In Azhal sub types, Analam, Ranjagam and Prasakam are affected.  
¾ In Iyyam sub types Avalambagam, Kilethagam and Santhigam are 
affected. 
¾ In In udal thaathukkal, 100% 0f cases have deranged suronitham, 79% of 
cases have deranged Oon and Kozhuppu, 59% of cases have deranged 
Senneer. 73% and 17% of cases have deranged Saaram and Enbu 
respectively. 
¾ Most of the Garpavaayu are from Neithal Nilam.  
¾ Most of the case have anemia and all of them were treated. 
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¾ Anger, fear, sadness, non vegetarian diet, Vali (Vatham) inducing diet 
more aggravating factors of this disease. 
¾ The clinical trial was conducted in 30 patients of PCOD with trial drug of 
Kalinga thylam – 15 ml with neeragaaram in empty stomach for the first 
three mornings after start of menstruation for 3 cycles. Sengottai valladhi 
legium – 2g twice a day for 48 days, except the days in which the patients 
taking kalinga thylam.   
¾ Patient is advised to follow the strict pathiyam, ie patient is asked to avoid 
Salt, Vaayu inducing foods and activities, fatty food and sexual inter 
course. Patient is asked to take plenty of vegetables, fruits and greens. 
¾ 46% of cases had very good improvement, 27% of cases had good 
improvement, 20% of cases had Moderate improvement and 7% of cases 
have nil improvements. 
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                                                              SUMMARY 
¾ The clinical trial was conducted in 30 patients of PCOD with trial drug of 
Kalinga thylam – 15 ml with neeragaram in empty stomach for first three 
mornings after the start of menstruation for 3 cycles. Sengottai valladhi 
legium – 2 g twice a day for 48 days   
¾ Clinical diagnosis of GARPAVAAYU was done in the basis of clinical 
features described in our text book.  
¾ Hematological and Urine examination and ulrasonography were done 
before and after treatment of trial drug. 
¾ The various Siddha aspect examinations were carried out and recorded. 
¾ GARPAVAAYU in Siddha aspect was correlated with PCOD in modern 
aspect. 
¾ Pharmacological study showed that the trial drug has Estrous cycle 
regulating activity without any adverse effect. It also has anti oxidant 
activity. 
¾ Observation of the trial drug in the clinical study was clinically effective. 
¾ Drugs regulated the menstrual cycle and reduced the body weight in obesed 
patients significantly. Drugs reduced the symptoms by balancing the vatham.  
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¾ The patients came with infertility and irregular menstruation due to PCOD were 
ovulated regularly and having regular menstruation in which some of the patient 
had conceived. 
¾ Their USG reports shown normal ovaries and uterus. Thus the trial drugs proved 
that they regulate the menstrual cycle in PCOD patients. 
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           CONCLUSION 
¾ The clinical trial of Kalinga thylam and Sengottai valladhi legium was 
conducted in 30 patients. 
¾ In the study, Out of the 30 cases, 46% of cases had very good 
improvement, 27% of cases had good improvement, 20% of cases had 
Moderate improvement and 7% of cases have nil improvements with trial 
drugs. The results were statistically significant and there were no clinically 
significant adverse reactions noted with trial drug.  
¾ Modern treatments cause side effects e.g . Clomiphene. Clomiphene 
should not be used for more than about six cycles. Long-term use of 
clomiphene may increase the risk of ovarian cancer.  
¾ Expenditure of the trial drug is cost effective, easily preparable and highly 
effective in Garpavaayu.  
¾ The clinical study was encouraging to do the extensive study in large 
sample of Garpavaayu patients with trial drug with proper diagnosis. 
 
    
 
 
 
ULTRASONOGRAPHY REPORTS IN BEFORE AND AFTER TREATMENT
S. No O P No Name Age M/UM Weight ROC LOC
BT AT BT AT BT 1C 2C 3C 
1 AH 4811 Anusia 24 UM 48 48 IR R 45 35 32 30
2 AE 3866 Priya 28 M 98 92 IR R 120 45 35 32
3 AE 1210 Aanandhi 24 UM 61 58 IR R 60 32 30 30
4 AB 754 Sheeja 19 UM 56 54 IR R 90 30 30 30
5 AE 4196 Rajeswari 30 M 56 53 IR R 180 A A A
6 AE 3059 Prameshwari 27 M 57 55 IR R 90 45 35 30
7 AF 4152 Prema 25 UM 63 58 IR R 60 33 30 30
8 AG 8043 Rasiya baanu 22 UM 53 52 IR R 50 32 30 30
9 AF 4135 Jaba 20 UM 62 59 IR R 90 50 42 35
10 AG 9190 Jayanti 19 UM 37 37 IR R 50 38 31 28
11 AB 2564 Anandhi 20 UM 60 55 IR R 90 32 31 28
12 AD 5859 Malathi 29 M 70 69 IR IR 180 A A A
13 AG 2553 Gayathri priya 19 UM 72 69 IR R 65 42 37 32
14 AF 1104 Saranya 17 UM 50 51 IR R 60 35 32 29
15 AD 7553 Malarvathana 26 UM 65 59 IR R 90 52 49 41
16 AG 4653 Tamil selvi 18 UM 85 80 IR R 90 55 47 39
17 AG 5592 Saraswathy 30 M 83 79 IR R 90 40 35 30
18 AF 2800 Lakshmi 21 UM 71 67 IR R 60 30 30 30
19 AF 3577 Chitra 25 M 76 75 IR IR 120 65 45 43
20 AG 1271 Madeswari 29 M 93 86 IR R 90 55 38 32
21 AG 4625 Rekha 33 M 67 63 IR R 60 45 35 30
22 AA 6229 Vijaya rani 34 M 61 57 IR R 45 32 30 30
23 Z 1860 Vijaya 31 M 59 56 IR R 90 35 30 30
24 AE 7129 Uma 21 UM 62 56 IR R 40 32 31 29
25 AE 5541 Thirupura sundari  36 M 66 62 IR R 90 32 30 30
26 AE 527 Kalai selvi 25 M 75 69 IR R 60 38 36 36
27 AF445 Anandi 21 UM 50 50 IR R 60 30 30 30
28 AG 4622 Poornima 23 UM 58 56 IR R 45 35 31 30
29 AG 2163 Magesh vani 30 UM 92 87 IR R 180 45 39 37
30 AE 8744 Vijaya lakshmi 32 M 64 59 IR R 45 35 32 P
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 PREPARATION OF TRIAL DRUGS 
KALINGA THYLAM 
fypq;f ijyk; 
thUfr;rh wPUspr;rh wUzr; rhW 
tiuepk;gr; rhWtHj;j khd NeaQ; 
NrUfr;rh tstdëw; iwe;J kl;lj; 
jpd;%d;wq; Fg;gfw;wpr; NrHfhyhf 
thUfrh Ue;jdj;jhHf; fpJfypq;f  
khj;ijy kynlhopf;F khjhe;jr; nre; 
ePUff;rhlhtp uj;jFd;kk; Nghf;F 
epiykyl;Lg; GOf;fisA ePf;Fq; fhNz 
       - rpj;j itj;jpa jpul;L 
Ingredients 
 Juice of citrullus colocynthus 
 Juice of Melia azhadiracta 
 Juice of Allium cepa 
 Juice of Lemon fruit 
 Castor oil                                                              -    equal amounts 
Preparation: 
 Take all the above mentioned ingredients in equal amounts. Boil them until it reaches 
the mezhugu patham, then filter and store the medicine.  
  
SENGOTTAI VALLADHI LEGIUM  
Neha; jPur;Nrq;nfhl;il ty;yhjpnrhy;Ntd; 
EZf;fkha;r; Nrq;nfhl;il gye;jhd;gj;J 
NkhaNt rhzpg;ghy; Rj;jp nra;J 
%f;Fntl;b apd;Dkjpy; Kiwiaf;NfS 
rhaNt nfhLNtyp gwq;fpg;gl;il 
rq;NfhL mKf;fuh rptdhH Ntk;G 
XaNtkhtpypq;fg;gl;ilNahL 
cj;jkNd tiff;F xUgye;jhndd;Nd 
vd;dNt fUQ;rPufk; f];Jhhp kQ;rs; 
,Ujpg;gpyp fLf;fha; thYYit Nfhl;lQ; 
nrhd;dnjhU apitnay;yh kpbj;JNtNw 
#uzkha; itj;jpl;Lr; nrhy;yf;NfS 
cd;dpKd;Rj;jpnra;j Nrq;nfhl;iljd;id 
cuypypl;Lf; nfhg;giuapd; Njq;fha; nuz;L 
vd;dNt nas;SnkhU gbjhd; nuz;L 
,bj;JNk mjpd;gpd;G #uzj;ijf;nfhl;Nl 
 
nfhl;bNa NrHj;njhd;wh apbf;Fk;NghJ 
FKwNt giznty;yk; mQ;Rgyk; NghL 
jpl;lk; ,urfw;G+uk; tpuhfd; mQ;R 
NrHj;jpbj;J ty;yhjp nra;Jnfhz;L 
el;lNt ty;yhjp me;jpre;jp 
ehnshd;W ntUfbjh dae;J nfhs;S 
Fl;lkhq; fpue;jpnahL miuahg;G #iy 
Fd;kNkhL tapw;Wtyp tha;T#iy 
#iyNahL #jfj;jpd; tha;T jPUk; 
nrhw;ngupa Nkfnky;yhk; nrhy;yhNjhLk; 
thiyahe; jpNufkJ rpj;jpahFk; 
kz;lye;jhd; gj;jpakha;f; nfhz;LtheP 
fhiyNa gj;jpae;jhd; nrhy;yf;NfS 
ifg;NghL GspGifAk; ngz;Ze;js;S 
ghNyhL kw;wnjy;yh kpr;rh gj;jpak; 
ghq;fhd cg;gjid tWj;Jf;nfhs;Ns 
      - gpukKdp fUf;fil #j;jpuk; 
Ingredients 
1. Purified Semecarpus anacardium              -          350gm 
2. Plumbago zeylanica   - 35gm  
3. Smilax chinensis   - 35gm 
4. Withania somnifera   - 35gm 
5. Azima tetracantha   - 35gm  
6. Crateava magna   - 35gm  
7. Indigofera asphalathoids   - 35gm  
8. Nigella sativa   - 35gm 
9. Curcuma aromatica   - 35gm 
10. Piper longum   - 35gm 
11. Pirer longum root   - 35gm 
12. Terminalia chebula   -     35gm 
13. Celastrus paniculata   - 35gm 
14. Costus species   - 35gm 
15. Dried coconut   -  2 nos 
16. Sesamum indicum seeds   - 2.8 litre 
17. Palm jaggery   - 175gm 
18. Purified Mercuric Chloride(pooram) -  20.5gm 
Preparation: 
  Powder the above ingredients separately except 1, 15, 16 and pound items 1, 15, 16  
separately and mix of them. Again pound these entire items until it reaches legium 
consistency.  
Dosage and administration: 
 This is an open trial. Kalinga thylam is given 15 ml in empty stomach for first three 
mornings after starting of menstruation for 3 consecutive cycles and Sengottai valladhi 
legium – 2 g twice a day for 48 days. Trial treatment period is 3 cycles. Patient have to visit 
once in 2 weeks for assessment and drug collection.  
Dietary regimen: 
 Avoid salt and tamarind taste and bitter taste food items. 
 Avoid smoking and sexual intercourse.  
 Advised to take milk. 
 Properties of the ingredients of the trial drugs: 
Mw;Wj;Jk;kl;b Citrullus colocynthis  - cucurbitaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
fpil vq;Nf Nrhk;gy; vq;Nf NfLwr;nra; thjf;  
fil vq;Nf ahw;Wf;fypq;f – kiljpwf;fpd; 
dz;il ailr;ry; vq;Nf Mapioahh; #jfj;jp 
Dz;il Ailr;ry; vq;Nf NahJ 
 Glucoside – colocynthin, colocynthein – resin, colocynthetin, pectin, gums 
 Abortifacient, puerperal disorders 
 Useful in hair growth and sterility. 
 
vYkpr;rk; gok;     Citrus acida - Rutaceae 
Rit  - Gspg;G 
tPhpak; -  ntg;gk; 
gphpT  -  fhHg;G 
jhfk; FefNeha; jhohrpypgjNeha;  
Ntfq; nfhSd;khjk; tPWgpj;jk; - khfz;Nzha; 
fd;d Neha; the;jpAk; Nghq; fl;Lthj;njhopypd; 
kd;d ndYkpr;rk; fdpia tho;j;J 
 Citric acid, phosphoric acid, malic acid, citrates of potassium, sugar, mucilage and 
ashes, hesperidin. 
 Refrigerant, anti - scorbutic, germicide, antiseptic 
 
kiy Ntk;G  Melia azadirachta    -  Meliaceae 
Rit  - ifg;G 
tPhpak; -  ntg;gk; 
gphpT  -  fhHg;G 
kyl;L GOTk; tapw;wpd;typAk; 
kyl;L tha;Tk; Nghklq;fpf; - nfhyl;L 
KiyNtQ; rpdNtw;fz;NzhjpkNk Nfsha; 
kiy Ntk;gpd; Ngiu tOj;J 
 Light yellow non-crystalline yellow resinous substance without alkaloidal properties, 
sugar, tannin 
 Emmenogogue, resolvent,  anthelmentic, antilithic , diuretic, astringent. 
 
ntq;fhak; Allium cepa -  Alliaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  -  fhHg;G 
ntg;g Kyq; fpue;jp tPwpuj;j gpj;jKld; 
nrg;G eh mf;fue;jPuhj;jhfk; - ntg;Gf; 
fLg;gWke; jQ;re;jp fhr tapw;Wg;gy; 
jLg;NgW ntq;fhaj; jhy; 
 Sulphur contains acrid volatile oil, quercetin 
 Emmenogogue, diuretic, Aphrodisiac, antiseptic. 
 
Nrq;nfhl;il Semecarpus anacardium - Anacardiaceae 
Rit  - ifg;G> tpWtpWg;G 
tPhpak; -  ntg;gk; 
gphpT  -  fhHg;G 
fpUkpfaQ; #iy fpue;jp jpkpH thjk; 
nghUK Fd;k Kz;Kyk; Gz;izj; - jUkh 
fhpKfpf; Fl;lq; fBtplghfk; Ngh 
nkhpKfpf; Fr;Rf khnkz; 
 Anacardic acid, anacardol (nonvolatile alcoholic, semecarpol, bhilawanol) 
 Powerful antiseptic, cholagogue, escharotics, digestive, nervine cardiac tonic, general 
respiratory stimulant. 
 
nfhbNtyp NtH Plumbago zeylanica - Plumbagineaceae 
Rit  - fhHg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
fl;btpuzq;fpue;jp fhy;fs iuahg;Gf; 
fl;b #iytPf;fk; fho;%y Kl;buj;jf; 
fl;L ePNuw;wq; fdj;j ngUtapW 
kl;Lq; nfhLNtypahk; 
 Plumbagin,  
 Alterative, gastric stimulant, appetizer. It has specific action on uterus. 
 
gwq;fpg; gl;il Smilax chinensis -  Lilliaceae 
Rit  - ,dpg;G 
tPhpak; - jl;gk; 
gphpT  -  ,dpg;G 
jhfk; gythje; jhJel;lk; Gz;gpsit 
Nkfq; fbfpue;jp tPo;%ye; - NjfKlq; 
Fl;il gfe;juNkw; nfhs; tkdk; Nghk; gwq;fpg; 
 gl;ilapid Ar;rhpj;Jg;ghH  
 Steroid saponins (0.5-3 %): chief components are sarsaparilloside, parillin, 
deglucoparillin, deglucorahmnoparillin, and sarsapogenin, β-sitosterol and stigmasterol, fat, 
sugar, glucoside, coluring matter. 
 Depurative, diaphoretic. stimulant, alterative, antisyphilitic, 
 rq;fk; Fg;gp Azima tetracantha - Salvadoraceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
Fug;ghd; fpue;jp fUq;Fl;lNuhfk; 
Kug;ghd NkfnkhopAq; - fUg;gf; 
fUq;fpue;jp nrt;thg;Gf; fl;BfSNkF 
kUQ; rq;fk; Fg;gpf; fwp 
 
rq;fk; NtHgl;il rspapUkiyr; Ruj;ij 
aq;fthjf;fLg;ig ahlijg;igg; - gq;fNk 
nra;Aq; fpue;jpiaAl;Bfhy; fpUkpiaapt; 
itae; jdpnyhopf;F khy; 
azimine, azcarpine and carpine. Roots has friedelin, lupeol, glutinol, ß – sitosterol 
diuretic, stimulant, astringent, antiperiodic, expectorant 
 
mKf;fuh Withania somnifera - Solanaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
nfhQ; JtHg;ghq; nfhbafaQ; #iyahp 
kpQ;Rfug;ghd; ghz;L ntg;Gjg;G – tpQ;rp 
KRTW NjhlKk; NghNkhfk; mdYz;lhk; 
mRtnfe;jpf; nfd;wwp 
The main constituents of ashwagandha are alkaloids and steroidal lactones. cuscohygrine 
,iron, pseudotropine, scopoletin, somniferinine, somniferiene , tropanol , withanine, 
withananine and withanolides A-Y. 
Among the various alkaloids, withanine is the main constituent. The other alkaloids are 
somniferine, somnine, somniferinine, withananine, pseudo-withanine, tropine, pseudo-
tropine, 3-a-gloyloxytropane, choline, cuscohygrine, isopelletierine, anaferine and 
anahydrine. Two acyl steryl glucoside viz. sitoindoside VII and sitoindoside VIII The leaves 
contain steroidal lactones, which are commonly called withanolides. The withanolides have 
C28 steroidal nucleus with C9 side chain, having six membered lactone ring. 
Alterative, aphrodisiac, tonic, deobstruent, diuretic, narcotic, abortifacient. Antiboitic 
 
rptdhH Ntk;G      Indigofera asphalathoids  - Fabaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
rha;Fkpl;bg;Gz; gok;Gz; rHkFl;lk; gpsit 
jPf;fLf;fhy; td;nghUNeha; rpe;Jkh – Neha;f;F 
tpijahjp Ntk;gpdh nka;f;foF fhiy 
Aijahj Ntk;gpdhYd; 
 
khtpypq;f kuk;   Crateva religeosa - Capparidaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
Ruq;fbapd; Nwhre; njhiyahj thj 
Kuk; ngWtp~q;fnshopAk; - muKq; 
fUkhtLtapYq; fz;lq; Rq; fz;zh 
nahL khtpypq;Ff;Fiu 
friedelin, lupeol, butilinic acid, diosgenin, gluco caparin, ß – sitosterol, tri acontine, tri 
acontanol, cetyl and ceryl alcs.  
Laxative, lithotriptic, Anti-inflammatory, oxytocic 
 
fUQ;rPufk;     Nigella sativa L.  - Ranunculaceae  
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
fUQ;rPufj;jhw; fug;ghndhL Gz;Zk; 
tUQ;rpuha;g;gPerK khWk; - mUe;jpdhy; 
fha;r;ry; jiy typAq; fz;typAk; NghKyfpy; 
tha;r;r kUe;njdNt it 
Hederin, thymoquinone, abscisic acid, flavonoids etc.  
Carminative, diuretic, emmenagogue, galactogogue, anthelmintic, stomachic, parasiticide, 
emollient. 
 
f];Jhhp kQrs;    Curcuma aromatica -  Zingiberaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
Gz;Zq; fug;ghDk; Nghfhf; fpUkpfSk; 
Ez;Zke;jhf;fpdpA ehrkhk; - tz;zkyHj; 
Njhj;Nj wsfkpd;Nd Rf;fpyKk; Gj;jpAkhq; 
f];Jhhp kQrSf;F fhz; 
Curdione, neocurdione, curcumol, tetramethylpyrazine and (R)-(+)-1,2-hexadecanediol were 
isolated from C. aromatica. 
Stimulant, tonic, carminative. 
 
jpg;gpyp  Piper longum Linn - Piperaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
fl;b vjpHepd;W fLNeha; vy;yhk; gzpAk; 
jpl;b tpidafYk; Njfnkj;j – Gl;bahk;  
khkDf;F khkndd kw;wtu;f;F kw;wtdhk; 
fhkndDk; jpg;gpypf;Fk; if 
Piperine and Piplartin 
Alterative, tonic, sedative, vermifuge, cholagogue, emmenagogue.  
 
ahidjpg;gpyp  Scindapsus officinalis - Araceae 
Rit  - fhHg;G 
tPhpak; - ntg;;gk; 
gphpT  - fhHg;G 
thjkWe; jPgdkh khwhf; fgq; fug;ghd; 
XJFuw; fk;kypia NahLq;fhz; - G+jyj;jpw; 
Nrhidia NeH ehrpdPH Njhyhr;R thrKk;Nghk; 
ahidapdw;wpg;gpypajhy;  
Scindapsin A and B, sterol. 
stomachic, stimulant, anthelmentic, sudorific 
 
fLf;fha; Terminalia chebula - Combretaceae 
Rit  -JtHg;G.,dpg;G>Gspg;G>ifg;G>fhHg;G 
tPhpak; -ntg;gk; 
gphpT  -,dpg;G 
jhil fOj;jf;fp jhYFwpaptplg;  
gPil rpypgjKw; NgjpKl – khil nal;lhj; 
Jhykpb Gz;thjNrhzp fhkhiy apuz; 
lhykpb Nghk;thpf;fhahy; 
Fruits contain astringent substances - tannic acid, Chebulinic acid, gallic acid etc. Resin and a 
purgative principle of the nature of anthraquinone and sennoside  
antibacterial and antifungal,laxative  
It has 18 amino acids, sugar, phosphoric acid, sucicinic acid and some other acids in minute 
quantities.  
The concentration of tannin decreases in fruit as it matures and the acidity increases.  
Resin and purgative principle of anthraquinone and sennoside nature is also present.  
 
thYOit mhprp  Celastrus paniculata - Celastraceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
tapw;W fLg;G typ khwhf;fpuhzp 
gapj;jpaq; fhrkyge;jQ; - rapf;fnthzhr;  
#jpfh thjKk; Nghe; njhy; thYOittpijf; 
Nfhjp itj;j ey;nkhopia NahH 
Oleum nigrum – an empyreumatic black oil 
Alterative, stimulamt, nervine tonicc, aphrodisiac, diaphoretic. 
 
Nfhl;lk;  Saussurea lappa 
Rit  - ifg;G. tpWtpWg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
jpl;b fTsfLfsQ; nrd;dp ehtha; 
nrwpgpzp nrg;gijg;G jhtHj;j %ij 
Kl;bnaUKistpuzQ; Rthr fhr 
%bfj;Njhl urplq;fz; Nkff; 
fl;b a[fy;yptplghfk; Nkff; 
fzk; ghy fpufnkhL jhJel;lk; 
nrl;b tU gpukpgpj;jkpit nahUq;Nf 
nrfiyAk; tpuzfhpf;Fr; Rfg;NgwhNk 
Essential oil (1.5%). Essential oil constituents (Aplotaxena 20%, Sesquiterpenes (60%), 
Saussuine alkaloid, Kushtin, Lactones, Costunolide, Palmitic Acid, Dihydrodehydrocostus, 
lactone, propyl acetate, lauric acid. 
Stimulant, stomachic, expectorant, tonic, diaphoretic 
 
vs;S  Sesamum indicum 
Rit  - ,dpg;G 
tPhpak; - ntg;gk; 
gphpT  - ,dpg;G 
vs;S kUe;ijf; nfLf;F Nkwdyhe; jpz;ikjU 
Ks;spiyiar; NrHf;F Kjpuj;ijj; - js;SkpU 
Fz;Zf; nfhsp nfhLf;Fq; fhrKz;lhk; gpj;jKkhk; 
Gz;Zf; fplHGhpAk; ghH 
glycerides of oleic and linoleic acids, stearin, palmitin and myristin. Sesamin, Liquid fatty 
acids are present to about 70 per cent., solid fatty acids 12 to 14 per cent.  
Emmenogogue, stimulant, tonic ,diuretic, lactogogue, laxative. 
 
 
 
Njq;fha; Cocos nucifera -Arecaceae 
Rit  - ,dpg;G 
tPhpak; - jl;gk; 
gphpT  - ,dpg;G 
neQ;rpw;wpkpUQ; nre;ePhpyOf;Fk; GilA 
kQ;R fg thjnkhL thjKNk – tpQ;Rkpse; 
njhq;fpdNj fHf;faHTe; JhaGj;jp ke;jKkhe; 
njq;fpdJ fz;lhw; nwsp 
Per 100 g, the green nut is reported to contain 77-200 calories, 68.0-84.0 g H2O, 1.4- 2.0 g 
protein, 1.9-17.4 g fat, 4.0-11.7 g total carbohydrate, 0.4-3.7 g fiber, 0.7-0.9 g ash, 11-42 mg 
Ca, 42-56 mg P, 1.0-1.1 mg Fe, 257 mg K, trace of beta-carotene, 0.4-0.5 mg thiamine, 0.03 
mg riboflavin, 0.8 mg niacin, and 6-7 mg ascorbic acid  
Coconut oil is one of the least variable among vegetable fats, i.e. 0.2-0.5% caproic-, 5.4-9.5 
caprylic-, 4.5-9.7 capric-, 44.1-51.3 lauric-, 13.1-18.5 myristic, 7.5-10.5 palmitic-, 1.0-3.2 
stearic-, 0-1.5 arachidic-, 5.0-8.2 oleic-, and 1.0-2.6 linoleic-acids (C.S.I.R., 1948-1976).  
 
gidnty;yk; Borassus flabelliformis - jaggery 
Rit  - ,dpg;G 
tPhpak; - jl;gk; 
gphpT  - ,dpg;G 
tl;L gdnty;yj;jhy; khHnghpr;ru; Fd;kkWk; 
Kl;Le; jphpNjh~k; Kd;dpw;fh – fl;Lglh 
The;jp Urpapd;ik thshAw;wpbDk; 
Rhe;jp ngUFnkd;Nw rhw;W 
Gum, fat, albuminoids, galactomannan,good source of biologically available riboflavin. 
Diuretic, demulcent, nutritive. 
 
G+uk; hydrargyrum sub - chloride. 
Rit  - cg;G. fhHg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
jpuz;l thjq; Fly; thjk; 
jPUQ;re;ep gjpd;Kd;W 
kUz;Nl Fj;J kiuahg;G 
kz;il #iy fghytpb 
guq;fp #iygw;fpue;jp 
gf;f#iy apitKjy; Nghk; 
,Uz;lNkdp nghd;dpwkhk; 
,JNt fw;gk; ,ak;gPNu 
Antiseptic, sialogogue, alterative, cholagogue, purgative. 
 Ricinoliate of glycerol or tri ricinolein, palmitin, stearin 
 Non irritant purgative, Emmenogogue  
 
 
 
Mkzf;F nea; Recinus communis(Caster oil ) – euphorbiaceae 
Rit  - ifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhHg;G 
Mkzf;F nea;ahy; eyKz;lhk; ahtHf;Fk;  
G+kzf;F Nkdp GhpFoNy – tha;kzf;ff;  
Nfhs;sp; tapWtpLq; NfhuKs;s thAtWk; 
Cs;spy; tUFd;kk; Nghk; XJ 
Ricin D - is a highly toxic protein, mol. wt. ~60 kDa, composed of two chains, A and B, 
connected by a single disulfide bridge 
ricinoleic acid (12-Hydroxyoleic Acid) comprises approximately 90% of the fatty acid 
composition the other fatty acids are Palmitic acid,Palmitoleic acid,Margaric acid, 
Margaroleic acid, Stearic acid, Dioxystearic acid, Oleic acid, Linoleic acid, Alpha-Linolenic 
acid,Arachidic acid, Eicosanic acid, Behenic acid, Erucic acid 
anti-inflammatory, anti-bacterial, Laxative, emollient   
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1.0 MATERIALS AND METHODS 
 
 
1.1 Test Drugs 
 
 The following medicinal plants were used in the study were collected and processed 
by the methods prescribed in standard text books of siddha medicines. 
 
1.1 Kalinga Thylam (KT) and Sengottai Valladhi Legiyam (SVL).  
KT was prepared by the method described in (Kannusaamy parambarai 
vaithiyam., pg no : 211-212) 
SVL was prepared by the method described in (brama muni karukkadai 
soothiram, pg no : 30) 
 
1.2 Preparation of drug for dosing 
 
 All drugs used for the study was suspended each time with 1% (w/v) solution of 
sodium carboxy methyl cellulose before administration. 
 
1.3 Drugs and chemicals 
 
 Fine chemicals used in these experiments were obtained from Sigma Chemicals 
company, U.S.A. Other analytical grade chemicals were obtained from S.d. Fine Chemicals 
Ltd., Mumbai. 
 
1.4 Experimental animals  
 
 Colony inbred animals strains of wistar rats of either sex weighing 200 - 250 g and 
swiss albino mice of either sex (18-25 g) were used for the pharmacological and 
toxicological studies. The animals were kept under standard conditions 12:12 (day/night 
cycles) at 220C room temperature, in polypropylene cages. The animals were fed on standard 
pelleted diet (Hindustan Lever Pvt Ltd., Bangalore) and tap water ad libitum. The animals 
were housed for one week in polypropylene cages prior to the experiments to acclimatize to 
laboratory conditions. The experimental protocol was approved by the Institutional Animal 
Ethical Committee (IAEC). 
1.5 Acute oral toxicity study     
 
Acute oral toxicity was conducted as per the OECD guidelines (Organization of 
Economic Cooperation and Development) 423 (Acute Toxic Class Method). The acute toxic 
class method is a stepwise procedure with 3 animals of a single sex per step. Depending on 
the mortality and /or moribund status of the animals, on the average 2-4 steps may be 
necessary to allow judgment on the acute toxicity of the test substance. This procedure 
results in the use of a minimal number of animals while allowing for acceptable data based 
scientific conclusion. 
 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) and the results 
allow a substance to be ranked and classified according to the Globally Harmonized System 
(GHS) for the classification of chemicals which cause acute toxicity 
 
 
Wistar albino rats of either sex weighing 200-250 g were fasted overnight, but 
allowed water ad libitum. Since the formulation is relatively non toxic in clinical practice the 
highest dose of 2000 mg/kg/p.o (as per OECD guidelines “Unclassified”) was used in the 
acute toxicity study.   
 
The animals were observed closely for behavioural toxicity, if any by using FOB 
(Functional observation battery). 
 
1.6 Repeated oral toxicity study  
Repeated oral toxicity studies can be used to get additional information regarding the 
toxicity profile of a chemical. Repeated oral toxicity studies are defined as those studies 
where the chemical is administered to the animal for a period covering approximately 10% of 
the expected life of the animal. Usually, the dose levels are lower than for acute studies and 
allow chemicals to accumulate in the body before lethality occurs, if the chemical possess 
this ability. 
Experimental procedure 
The following experimental procedure was followed to evaluate the repeated oral 
toxicity study of  
1. Kalinga Thylam (KT) and Sengottai Valladhi Legiyam (SVL). 
 
Group I : Control animals received 1% Sodium carboxy methyl cellulose (CMC), 2   
ml/kg/p.o. for 21 days  
Group II : Drugs suspended in CMC was given at the dose Level of 500 mg/kg/p.o.  for 
21 days 
 Body weight, food intake and water intake was recorded at two intervals with 
simultaneous observation for toxic manifestation and mortality, if any. At the end of 21 days 
treatment all the animals were sacrificed by over dosage of ether anaesthesia. Blood was 
collected and used for haematological studies. Section of liver, kidney, and heart were 
dissected out and kept in 10% formalin for histopathological studies. 
1.7 Biochemical studies 
Aspartate aminotransferase (AST) 
 Aspartate aminotransferase was estimated using commercial AST kit (Span 
Diagnostics) by the method of Reitman and Frankel (1957). 
 
Alanine aminotransferase (ALT) 
 Alanine aminotransferase was estimated using commercial AST kit (Span 
Diagnostics) by the method of Reitman and Frankel (1957). 
Alkaline phosphatase (ALP) 
 Alkaline phosphatase was assayed using commercial ALP kit (Span Diagnostics)  by 
the method of King (1934). 
Urea   
 Urea was assayed using the commercial kit (Span Diagnostics) by the method of 
Coulambe  et al., (1965). 
1.8 Haematological studies 
 
Erythrocyte count 
 Erythocyte count was estimated by Hemocytometer method of Ghai (1995). 
Total Leukocyte Count (WBC) 
 Total Leukocyte Count was estimated by Hemocytometer method of John (1972). 
Haemoglobin  
 Haemoglobin was estimated by method of Ghai (1995). 
 
1.9 Swimming  induced stress in irregularities of estrous cycle in rats 
 
Female rats (125-150 g) were randomized into groups of six animals each. Vaginal 
smear was taken at 9 am daily to evaluate the status of estrous cycle. Those animals showed 
the regular estrous cycle were selected for the study. The animals were divided into 
following groups and they received the respective regimen of treatment. 
 
Group I - Control  
( n = 6) 
 
Group II - Test drug   (KT + SVL, 500 mg/kg/p.o) 
( n = 6) 
 
The animals in Group I and II were given swimming stress for 30 mts in a vertical tub 
containing water upto 15 mm high maintained at room temperature. The vaginal smears of 
the stressed animals were examined for the stages of estrous cycle.   The animals showed the 
diestrous stage after the swimming test were given the test drug at the dose of 500 mg/kg/p.o 
for 3 days and animals in the control group received vehicle only for same period. At the end 
of 3rd day after the drug/vehicle treatment the vaginal smears of all the animals were tested 
for the different stages of estrous cycle for the 4 consecutive days. The same experiment is 
continued for 4 cycles after the induction of swimming stress as explained above.        
  
 
1.10 In Vivo Antioxidant study 
 
Samples of serum collected from  rats treated with test drugs were assayed for GSH 
(Moron et al , 1979)  and LPO (Yagi, 1976)  and the results were compared with  control 
group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.0 Results 
 
 
2.1 Preliminary basic, acidic radicals and phytochemical studies   
 
The qualitative chemical analysis and acidic, basic radicals assay of the drugs showed 
the presence of phytoconstituents and minerals as depicted in (Table 1). 
 
2.2 Acute oral toxicity study 
 
KT and SVL at the dose of 2000mg/kg/po did not exhibit any mortality in rats. As per 
OECD 423 guidelines the dose is said to be “Unclassified” under the toxicity scale. Hence 
further study with higher doses was not executed.  
 
2.3 Repeated oral toxicity for 21 days 
 
Test drug KT and SVL at the dose of 500 mg/kg/po when administered orally for 21 
days in rats did not show toxicity in renal functions. However the drug exhibited significant 
reduction in RBC count and elevation of marker enzyme levels of liver (Table 2 and 3). 
  
2.4 Antioxidant activity  
 
At the end of 21 days repeated oral toxicity study when the plasma of drug treated 
animals was examined for GSH activity, the level of GSH activity was increased 
significantly (p>0.001) in test groups (Table 4). 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 
 
Normal menstrual cycle in women is often disturbed by physical and mental 
stress. These changes in menstrual cycle may be attributed to psychological stress 
compounded by endocrine disturbances. Menstrual irregularities in women in 
reproductive age may also be attributed to the work environment, circardian changes 
precipitated by working in night shifts and odd hours of the day, life style etc. 
 
Irregular menstruation is regularized by siddha medicinal practitioners using 
herbo mineral preparations. Even these drugs are also used to treat clinical conditions 
like polycystic ovary. Though an model similar to human menstrual cycle cannot be 
developed in animals, stress induced changes in estrous cycle of rat can be used as a 
model to screen drugs which correct menstrual irregularities. The estrous cycle in rats 
will be completed in ¾ days and this will ease the cost and time of study for 5-6 
cycles. The diestrous, proestrous, frack estrous and meta estrous can be identified by 
examining the vaginal cytology of rats. 
  
The swimming stress is an ideal model, can be taken for evaluating drugs 
acting on the regularization of estrous cycle in rats. 
 
In the present study all stressed rats uniformly showed diestrous phase of 
estrous cycle. The pretreatment with test drugs for 3 days before induction of 
swimming stress, helped to proceed the estrous cycle normally from diestrous to 
estrous, whereas the groups received no treatment were still on diestrous phase 
continuously for 3 cycles as evidenced by the vaginal cytology. 
The exact mechanism of test drug that showed the reversal of irregularity on 
the estrous cycle of the rats after swimming test is not fully understood. The reversal 
of irregularity and maintenance of estrous cycle by drug treatment for another 3 
consecutive cycles over untreated animals clearly establishes the positive correlation 
of results between clinical and experimental studies. Rat shows polyestrous, hence the 
results obtained from the rat study could be extrapolated to human study, is debatable. 
The hormonal profile of normal and stressed rats, before and after treatment and their 
reversal, if any, may give some more authentic data about the efficacy of drug in the 
treatment of menstrual irregularities in human beings. 
 
The another important question to be answered on the efficacy of the drug 
treatment to prevent the irregularity of estrous cycle in 3-4 cycles is sustainable or not 
for a longer period or the drug treatment should be continued after a washout  period 
of 3-4 cycles to maintain the regular cycle on a sustained basis.                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Qualitative analysis of Acidic/Basic radicals and phytochemical 
constituents in test drugs 
 
 
Procedure Observation inference 
Test for Calcium : 2 ml of 
extract is taken in a clean test 
tube. To this add 2 ml of  4% 
ammonium oxide solution.   
No white precipitate is formed Absence of calcium  
Test for Sulphate : 2 ml of the 
extract is added to 5 % barium 
chloride solution. 
No white precipitate is formed  Absence of Sulphate  
Test for Chloride : The extract 
is treated with Silver nitrate 
solution  
 No white precipitate is formed Absence of Chloride 
Test for carbonate : The 
substance is treated with Conc. 
HCl. 
No effervescence is formed  Absence of carbonate 
Test for Starch : The extract is 
added with weak iodine solution 
Blue colour is formed Presence of starch  
Test for Iron (Ferric) : The 
extract is treated with glacial 
acetic acid and potassium 
ferrocyanide  
No blue colour is formed Absence of Ferric iron 
Test for Iron (Ferrous) : The 
extract is treated with Conc. 
HNO3 and ammonium 
thiocynate 
No Blood red colour is formed Absence of Ferrous iron 
Test for phosphate : The 
extract is treated with 
ammonium molybdate and 
conc. HNO3 
Yellow precipitate is formed Presence of phosphate 
Test for Tannic acid : The 
extract is treated with Ferric 
chloride  
Blue black precipitate is 
formed 
Presence of Tannic acid 
Test for Unsaturation : 1 ml of 
Potassium permanganate 
solution is added to the extract.   
Does not get decolourised  Absence of unsaturated 
compound 
Test for saponins: Dilute 
extract+ 1ml of distilled water 
shake well. 
Froth formation Presence of saponins 
Test for sugars :  
 Benedict method ; 5ml of  
Benedict solution heated gently 
then add 8 drops of diluted 
No colour change 
 
 
 
Indicates the Absence of 
sugar 
 
 
extract then heated in a boiling 
water bath. 
 
Molisch test; Dilute extract+2 
drops of Molisch+3ml 
conc.H2SO4. 
    
 
  
No Reddish violet zones 
appeared 
 
 
 
Absence of carbohydrate 
Test for steroids : Liberman 
Burchard test ; Dilute extract +2 
ml acetic 
anhydride+conc.H2SO4 . 
No Formation of red colour  Absence of steroids 
Test for amino acids: Dilute 
extract +2ml of Ninhydrin’s 
soln . 
Formation of  violet colour Presence of  amino acids 
Test for proteins: Biuret 
method ; 1ml of dilute 
extract+1mlof5%CuSO4+ 
1%NaOH. 
Formation of Violet   colour Presence of proteins 
Test for Flavanoids : Dilute 
extract+ mg  bits+2drops of 
conc.HCl  and gently heated. 
No formation of pink colour Absence of Flavanoids 
Test for phenol; Dilute 
extract+2drops of FeCl3 soln. 
 Deep green colour is formed Presence of phenols 
Test for Tannins ; dilute 
extract +2ml of 10%lead acetate 
add. 
White precipitate formed Presence of tannins 
Test for alkaloids; 
 Mayer’s method;1ml of dilute 
extract + 1ml reagent. 
 
Dragendroff’s method; 1ml of 
dilute extract+ 1ml of reagent. 
 
Appearance of cream colour 
precipitate 
 
 
 
Appearance of orange colour 
precipitate 
 
Presence of alkaloids 
 
 
 
Presence of alkaloids 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
 
Preliminary acid, basic radicals and phytochemical screening 
S.No. Constituents KT SVL 
1. Calcium + + 
2. Iron (Ferric) + - 
3. Iron (Ferrous) - + 
4. Sulphate + + 
5. Chloride + + 
6. Carbonate  + - 
7. Starch - + 
8. Phosphate - - 
9. Tannic acid + - 
10. Unsaturated + + 
11. Sugar + + 
12. Alkaloids + + 
13. Steroids Trace + 
14. Protein + + 
15. Tannins + + 
16. Phenols + - 
17. Flavanoids - - 
18. Saponins - - 
19. Amino acid + + 
20. Cardiac 
Glycosides 
+ + 
21. Terpenoids + + 
 
 
 
 
Table 2 
 
Effect of Siddha Formulations (KT + SVL)  on Haematological parameters 
 after 15 days repeated oral dosing (500 mg/kg) 
 
 
Groups Hb (gm/100ml) RBC (millions/cu.mm)
Control  12.45±0.4113 5.20±1.047 
 
Test  
(500mg/kg. p.o.,)
14.67±0.5164** 6.467±2.033**
 
 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
                          **P<0.003 as compared with that of control. 
Table 3 
 
Effect of Siddha formulation (KT + SVL ) on Biochemical markers of liver  
and kidney after 15 days repeated oral dosing (500 mg/kg/po) in rats  
 
Groups ALP (K.A.Units) AST  
(IU/L) 
SGOT 
ALT  
(IU/L) 
SGPT 
Urea 
(mg/100ml) 
BUN 
(mg/ 100ml) 
Cholesterol 
mg/dl 
Control 2.973±0.3929 62.89±1.906 25.48±2.93 16.38±2.12 7.52±0.84 53.75±6.90 
Test 
(500mg/kg. 
p.o.,) 
7.850±0.2074 *** 153.3±5.164 *** 64.75±0.88 *** 19.93±0.79 ns 8.92±0.37ns 59.18±4.65 
 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
***P<0.001 as compared with that of control. 
ns – non significant when compared to control groups  
 
Table 4 
 
Anti oxidant activity of (KT + SVL ) after 15 days repeated oral dosing (500 mg/kg) 
 
 
Groups 
 
LPO GSH 
Control 
 
0.75 ± 1.37 13.56 ± 0.632 
Test       
(500mg/kg. p.o.,) 
0.21 ± 3.40*** 47. 56 ± 0.339*** 
 
N=6; Values are expressed as mean ± S.D followed by Student T- Test. 
***P<0.001 as compared with control.  
 
Table 5 
 
Effect of  (KT + SVL ) treatment in stress induced disturbance in estrues cycle in 
female rats   
 
Groups Estrus cycle in days  
 
Diestrus 
0 days 
Proestrus 
1st days 
Fruek estrus 
2 nd days 
Frauk estrus 
3rd days 
 
Meta estrus 
4 th day 
Control 
group before 
stress 
6/6 6/6 4/6 5/6 6/6 
Test group 
before stress 
(500mg/kg. 
p.o.,) 
6/6 6/6 5/6 6/6 5/6 
Control 
group after 
stress 
6/6 0/6 1/6 0/6 0/6 
g Test group 
after stress 
(500mg/kg. 
p.o.,) 
6/6 5/6 6/6 5/6 6/6 
 
Data show the number of animals (n=6) in each group showed different stages of oestrous 
cycle observed by vaginal cytology, starting from diestrous to metaestrous at 9 am on the 
days of examination.  
 
g The drug treatment was given for 3 days prior to the induction of stress.   
PROTOCOL      
 AN OPEN TRIAL OF SIDDHA DRUG  
           SENGOTTAI VALLADHI LEGIUM WITH KALINGA  
   THYLAM FOR THE TREATMENT OF GARPAVAYU (PCOD)   
                                                                               BY 
                              Dr.P.RAJALAKSHMI,M.D(s) Student, 
       Department of Maruthuvam, 
       National Institute of Siddha, 
       Chennai – 47.  
 1. BACKGROUND         
  Patients suffering from polycystic ovarian disease (PCOD) is characterized by 
scanty or absent menses, multiple cysts on the ovaries and infertility. These cysts occur by 
accumulation of many incompletely developed follicles in the ovaries when regular changes 
of a normal menstrual cycle and ovarian functions are disrupted. The ovary is enlarged 2 to 5 
times and produces excessive amounts of androgen and estrogenic hormones.  
This PCOD is correlated with GARPAVAYU mentioned in Agathya mamunivar 
ayulvedham 1200 
            ‘nghUkp uj;je;jd;id kwpj;Jg;Nghj kpfTk; typAz;lhq; 
 FUjp Nruh tapWtypNghq; nfhs;Sq; fh;g;ge;jid aopf;Fk; 
     tUb apLg;G File;Jisf;Fk; tyj;ij kpfTk; kpWf;fpWf;fp 
     ngUfg;gizf;F nkdg;nghpNahh; NgRq; fh;g;gthAtpNj’ 
As per Saint Agathyar, Garpavayu with the symptoms of irregular menstruation, 
dysmenorrhea, infertility, missed abortions, obesity, low back pain and constipation. 
Nowadays the female infertility is raised by PCOD which is one of the causes for infertility, 
may be due to stress and altered dietary habits. During 2005 – 2006, approximately 1000 
cases of Soothaga noi (including GARPAVAYU) were recorded in out patient department of 
Ayothidoss Pandithar Hospital of the National Institute of Siddha.  It is proposed to evaluate 
the efficacy of Sengottai valladhi Legium with Kalinga thylam for the treatment of 
GARPAVAYU (PCOD).        
 
 2. AIMS  
(a) Primary aim  
 To assess the efficacy of Sengottai valladhi Legium with Kalinga 
thylam for the treatment of GARPAVAYU (PCOD). 
(b) Secondary aim  
               To find out side - effects of the drug, if any. 
 
3. POPULATION & SAMPLE  
The population consists of PCOD patients [Who show multiple cysts or enlarged 
ovary in their ultrasonogram (USG) report ] satisfying the inclusion and exclusion criteria 
mentioned below. 
           The sample consists of PCOD patients attending the OPD of Ayothidoss Pandithar 
Hospital of the National Institute of Siddha,   Chennai-47. 
 
4. INCLUSION CRITERIA 
                                                1. Age 15 -45 years    
      2. Willing to attend IP/OP treatment                                                                     
3. Willing to get purgation for the treatment purpose   
5. EXCLUSION CRITERIA 
1. Cardiac disease                                                                                        
2. Pregnancy and lactation 
                                                3. Hypertension 
                                                4. Peptic ulcer    
6. WITHDRAWAL CRITERIA 
During trial treatment, if the patient develops any of the following, 
   she will be withdrawn from the study.  
                                           1. Severe abdominal pain.                                                                                         
2. Heavy menorrhagia.                                                      
3. Any other acute illness 
7. TRIAL DRUG AND DURATION 
                                                Kalingadhi thylam – 15 ml in empty stomach for first three 
                                                mornings after start of menstruation for 3 cycles. 
Sengottai valladhi legium – 2 g twice a day for 48 days   
Trial treatment period is 3 cycles. 
8. SAMPLE SIZE 
                       The trial size is 30 patients. 
 
9. TESTS AND ASSESSMENT 
      (a) CLINICAL  ASSESSMENT 
Irregular menstruation, amenorrhea, oligomenorrhea, 
dysmenorrhea, infertility, spontaneous abortions, obesity, 
hirsuitism, constipation.     
   
                (b) ASSESSMENT BY INVESTIGATION 
                      BLOOD 
                         TC (cells / cu mm), DC (%), ESR (mm), Hb (g %), 
                   Blood sugar (mg %).                 
URINE    
Albumin, Sugar, Deposit, Neerkuri, Neikuri 
 
ULTRASONOGRAM  
Abdomen and Pelvis  
(c) ASSESSMENT BY SIDDHA ASPECT 
Naa, Niram, Mozhi, Vizhi, Malam, Moothiram (neer kuri and 
nei kuri), Sparisam, Naadi. 
10. CONDUCT 
                        Patients satisfying inclusion and exclusion criteria are selected for 
the study. Informed consent will be obtained from the patients. 
The trial patients will be issued drugs for 15 days at a time. They will be 
instructed to come for next clinic visit after 15 days. Also they will be asked to bring 
back the unconsumed drug during their next visit and return the same. 
11. FORMS 
                  Form -1 
                        Selection proforma – used before admission to the trial 
Form -2 
                        Assessment proforma – used during clinic visits once in 15 days 
12. ANALYSIS 
Paired t - test for before and after treatment means for objective 
parameters. 
Paired chi - squared test for before and after treatment proportions for 
signs and symptoms.                                                                                                        
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CONSENT FORM 
Certificate by Investigator 
I certify that I have disclosed all details about the study in the terms readily understood 
by the patient. 
Date ……………..      Signature …………………………. 
Name ……………………………… 
Consent by Patient 
I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
I, exercising my free power of choice, hereby give my consent to be included as a subject 
in the clinical trial of  SengottaiValladhi legium with Kalinga thylam for the treatment of 
Garpavayu (PCOD). 
Date ………………..     Signature ……………………………………… 
Name ………………………………………….. 
Date ……………….     Signature of Witness ………………………….. 
Name ………………………………………….. 
Relationship………………………………….... 
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